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Abstract
Concerns about the completeness and accuracy of reporting of randomized clinical trials (RCTs) and the
impact of poor reporting on decision making have been documented in the medical field over the past several
decades. Experience from RCTs in human medicine would suggest that failure to report critical trial features
can be associated with biased estimated effect measures, and there is evidence to suggest that similar biases
occur in RCTs conducted in livestock populations. In response to these concerns, standardized guidelines for
reporting RCTs were developed and implemented in human medicine. The Consolidated Standards of
Reporting Trials (CONSORT) statement was first published in 1996, with a revised edition published in
2001. The CONSORT statement consists of a 22-item checklist for reporting a RCT and a flow diagram to
follow the number of participants at each stage of a trial. An explanation and elaboration document not only
defines and discusses the importance of each of the items, but also provides examples of how this information
could be supplied in a publication. Differences between human and livestock populations necessitate
modifications to the CONSORT statement to maximize its usefulness for RCTs involving livestock. These
have been addressed in an extension of the CONSORT statement titled the REFLECT statement: Methods
and processes of creating reporting guidelines for randomized control trials for livestock and food safety. The
modifications made for livestock trials specifically addressed the common use of group housing and group
allocation to intervention in livestock studies; the use of deliberate challenge models in some trials and the
common use of non-clinical outcomes, such as contamination with a foodborne pathogen. In addition, the
REFLECT statement for RCTs in livestock populations proposed specific terms or further clarified terms as
they pertained to livestock studies.
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Impacts
• Complete and accurate reporting of randomized controlled trials is
necessary to allow the reader of the trial to evaluate internal and external
validity.
• The REFLECT statement provides a checklist of items to include when
reporting randomized controlled trials conducted in livestock and food
safety.
• This explanation and elaboration document provides details for trial
authors and reviewers using the REFLECT statement checklist.
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Abstract
Concerns about the completeness and accuracy of reporting of randomized
clinical trials (RCTs) and the impact of poor reporting on decision making
have been documented in the medical field over the past several decades. Expe-
rience from RCTs in human medicine would suggest that failure to report crit-
ical trial features can be associated with biased estimated effect measures, and
there is evidence to suggest that similar biases occur in RCTs conducted in
livestock populations. In response to these concerns, standardized guidelines
for reporting RCTs were developed and implemented in human medicine. The
Consolidated Standards of Reporting Trials (CONSORT) statement was first
published in 1996, with a revised edition published in 2001. The CONSORT
statement consists of a 22-item checklist for reporting a RCT and a flow dia-
gram to follow the number of participants at each stage of a trial. An explana-
tion and elaboration document not only defines and discusses the importance
of each of the items, but also provides examples of how this information could
be supplied in a publication. Differences between human and livestock popula-
tions necessitate modifications to the CONSORT statement to maximize its
usefulness for RCTs involving livestock. These have been addressed in an exten-
sion of the CONSORT statement titled the REFLECT statement: Methods and
processes of creating reporting guidelines for randomized control trials for live-
stock and food safety. The modifications made for livestock trials specifically
addressed the common use of group housing and group allocation to interven-
tion in livestock studies; the use of deliberate challenge models in some trials
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The randomized clinical trial is a very beautiful tech-
nique, of wide applicability, but as with everything
else, there are snags. When humans have to make
observations, there is always the possibility of bias
(Cochrane, 1972).
The randomized controlled trial (RCT) is the gold
standard for evaluating the efficacy of therapeutic and
preventive interventions. In livestock populations, RCTs
can be used to evaluate the efficacy of interventions
related to animal health and productivity, as well as food-
safety outcomes. However, trials that do not employ
sound methodologies are associated with biased-effect
estimates (Schulz et al., 1995; Moher et al., 1998; Juni
et al., 2001). Biased trial results have the potential to mis-
lead decision making by clinicians, researchers and policy
makers, which ultimately impacts livestock producers and
the general public. The reader of a published clinical trial
cannot know the exact methods used to conduct the trial,
as the only information available to the reader is that
provided in the publication. Therefore, it is essential that
authors of clinical trials provide complete and accurate
details of the methods used in the trials in the
publication.
Incomplete and inaccurate reporting in published
livestock intervention trials
The basic criteria essential to the validity of RCTs have
been reviewed in the veterinary literature (Ribble, 1990;
Lund et al., 1994; Dohoo, 2004). However, despite the
availability of these criteria, the quality of reporting of
intervention trials remains poor. An assessment of the
quality of RCTs published in one journal revealed that
although some of the trials provided information on
methodological features, many others failed to do so
(Elbers and Schukken, 1995). These trials lacked informa-
tion related to the method of treatment allocation, the
grouping of animals relative to treatment allocation, the
use or non-use of blinding and the method of statistical
analysis (Elbers and Schukken, 1995). Further, several sys-
tematic reviews in pre-harvest food safety (Denagamage
et al., 2007; O’Connor et al., 2008) and animal health
(O’Connor et al., 2006; Wellman and O’Connor, 2007;
Burns and O’Connor, 2008) have noted a lack of report-
ing of group allocation methods; blinding and details
related to intervention protocols, outcome assessments
and statistical analysis methods in some published clinical
trials. This lack of consistency in reporting makes it
almost impossible to summarize sufficient data appropri-
ately, thereby affecting the ability to arrive at an overall
conclusion on a particular intervention or outcome. For
example, in 100 randomly selected trials on animal health
or production outcomes, only 67% reported random
allocation to intervention group, 35% clearly described
the number of animals housed together in a group, 4%
reported the use of double blinding where blinding was
feasible and 62% reported the number of study units lost
to follow-up during the trial (Sargeant et al., 2009a). In
an evaluation of 100 pre-harvest food-safety trials, ran-
domization, double blinding and the number of subjects
lost to follow-up were reported in 46%, 0% and 43% of
trials respectively, and the number of animals housed
together was stated in 52% of the trials (Sargeant et al.,
2009b).
Experience gained from RCTs in human medicine
would suggest that failure to report critical trial features
can be associated with biased estimates of effect measures,
and there is evidence to suggest that similar biases occur
in RCTs conducted in livestock populations. A systematic
review of trials evaluating the efficacy of vaccination for
the treatment of pink-eye in cattle found that trials not
reporting random allocation to intervention group and
blinding were more likely to conclude that the vaccine
was efficacious than trials where these features were
reported (Burns and O’Connor, 2008). Similarly, evalua-
tions of 100 randomly selected trials with animal health
or production outcomes and 100 randomly selected trials
with food-safety outcomes revealed significant associa-
tions between the proportion of positive treatment effects
within trials and failure to report trial features, such as
random allocation to intervention group, exclusion
criteria for study subjects, details of the intervention pro-
tocol, animal signalment and details of the measurement
of all outcomes (Sargeant et al., 2009a,b).
Improving the reporting of RCTs in the medical
literature: The CONSORT statement
Concerns about the completeness and accuracy of report-
ing of RCTs have been documented in the medical field
over the past several decades (DerSimonian et al., 1982;
Pocock et al., 1987; Gotzsche, 1989; Schulz et al., 1994;
and the common use of non-clinical outcomes, such as contamination with a
foodborne pathogen. In addition, the REFLECT statement for RCTs in live-
stock populations proposed specific terms or further clarified terms as they
pertained to livestock studies.
Received for publication November 2, 2009
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Sonis and Joines, 1994; Ah-See and Molony, 1998). In
response to these concerns, standardized guidelines for
reporting RCTs were developed and have been imple-
mented. The Consolidated Standards of Reporting Trials
(CONSORT) statement was first published in 1996 (Begg
et al., 1996). A revised version was simultaneously pub-
lished by four leading medical journals in 2001 (Moher
et al., 2001b,c,d,e). The CONSORT statement consists of
a 22-item checklist for reporting an RCT and a flow dia-
gram to follow the number of participants at each stage
of a trial. The items for the checklist were selected
because there was empirical evidence in the literature
indicating the potential for biased estimates of treatment
effects when these items were not reported, or because
the information was deemed essential to evaluate the
reliability or relevance of the findings (Moher et al.,
1998). An explanation and elaboration document not
only defines and discusses the importance of each of the
items, but also provides examples of how this information
could be supplied in a publication (Altman et al., 2001).
The CONSORT statement document is currently
endorsed by several hundred journals (http://www.consort-
statement.org), including two veterinary journals: the
Equine Veterinary Journal and The Veterinary Journal
(Higgins, 1997). Evaluations of RCTs since implementa-
tion of the CONSORT statement suggest that the state-
ment has improved the quality of reporting of RCTs
(Moher et al., 2001a; Plint et al., 2006; Kane et al., 2007).
Extensions of the CONSORT statement have been
developed for cluster trials (Campbell et al., 2004a, 2005,
2006), harms (Ioannidis et al., 2004), herbals interven-
tions (Gagnier et al., 2005, 2006a,b,c), non-pharmacologi-
cal interventions (Boutron et al., 2008) and abstracts
(Hopewell et al., 2008).
Modifications to the CONSORT statement for use in
trials involving livestock species
Differences between human and livestock populations
necessitate modifications to the CONSORT statement to
maximize its usefulness for RCTs involving livestock.
These have been addressed in an extension of the CON-
SORT statement titled the ‘REFLECT’ statement – The
REFLECT statement: Methods and processes of creating
reporting guidelines for randomized control trials for live-
stock and food safety (O’Connor et al., 2010a,b,c,d,e).
The modifications to the CONSORT checklist recom-
mended for livestock populations in the REFLECT state-
ment for livestock and food-safety intervention studies
are presented in Table 1. Although many of the checklist
items from the CONSORT statement remain unchanged,
the modifications made for documentation of livestock tri-
als (O’Connor et al., 2010a,b,c,d,e) specifically addressed
the common use of group housing and group allocation
to intervention in livestock studies, the use of deliberate
challenge models in some trials and the common use of
non-clinical outcomes, such as contamination with a food-
borne pathogen. In addition, the REFLECT statement for
RCTs in livestock populations proposed specific terms or
further clarified terms as they pertained to livestock pop-
ulations. The term ‘participant’ in the original CONSORT
statement was limited to refer only to animals’ owners/
managers, who consent to participate in the trial. The
term ‘study unit’ was preferred and recommended in the
REFLECT statement for the units within the study. This
term was used instead of ‘animal unit’, as it is common
that a part of an animal, such as a hoof, teat or eye,
be allocated to treatment. Study units may further be
classified as allocation units and outcome units. For
example, a study may allocate udder halves to receive the
treatment; therefore, the allocation unit is the udder half.
However, the outcome may be measured on the individ-
ual teat (i.e. the outcome unit).
The objective of this explanation and elaboration
document is to define each item modified from the
CONSORT checklist for the REFLECT statement for live-
stock and food safety, to provide a rationale for its inclu-
sion and to provide illustrative examples of how the item
might be reported for each REFLECT item. The examples
are derived from previously published studies in the
animal health/production and pre-harvest food-safety
literature.
Definitions
Challenge trial
A study design where the investigator controls allocation
to intervention and disease occurrence. In therapeutic
challenge trials, the investigator uses a model to induce
disease, and then allocates the study units to receive the
therapeutic intervention. The outcome of interest is often
clinical improvement. In therapeutic challenge trials with
health and production outcomes, the condition of interest
is commonly exposure to an infectious pathogen or a
metabolic disease, such as fatty liver in dairy cattle.
In preventive challenge trials, the investigator allocates
the study units to receive the preventive intervention, and
then uses a disease model to induce disease. The outcome
of interest is often prevention of clinical signs. For pre-
ventive challenge studies with food-safety outcomes, the
study often ensures exposure to the pathogen of interest.
Although challenge trials do not always involve an
infectious-disease outcome, this is a common model in
livestock populations and therefore, throughout the
text, most references to challenge trials are limited to
infectious-agent models.
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Table 1. Checklist of Items for the REFLECT statement: reporting guidelines for randomized control trials in livestock and food safety
Paper section and topic Item Descriptor of REFLECT statement item
Reported
on page no.
Title & Abstract 1 How study units were allocated to interventions (e.g. ‘random allocation’,
‘randomized’ or ‘randomly assigned’). Clearly state whether the
outcome was the result of natural exposure or was the result of
a deliberate agent challenge
Introduction Background 2 Scientific background and explanation of rationale
Methods Participants 3 Eligibility criteria for owner/managers and study units at each level
of the organizational structure, and the settings and locations where
the data were collected
Interventions 4 Precise details of the interventions intended for each group, the level at
which the intervention was allocated and how and when
interventions were actually administered
4b Precise details of the agent and the challenge model, if a
challenge study design was used
Objectives 5 Specific objectives and hypotheses. Clearly state primary and
secondary objectives (if applicable)
Outcomes 6 Clearly defined primary and secondary outcome measures and the
levels at which they were measured and, when applicable, any
methods used to enhance the quality of measurements (e.g. multiple
observations and training of assessors)
Sample size 7 How sample size was determined and, when applicable, explanation of
any interim analyses and stopping rules. Sample size considerations
should include sample size determinations at each level of the
organizational structure and the assumptions used to account
for any non-independence among groups or individuals
within a group
Randomization – Sequence generation 8 Method used to generate the random allocation sequence at the
relevant level of the organizational structure, including details of
any restrictions (e.g. blocking and stratification)
Randomization – Allocation concealment 9 Method used to implement the random allocation sequence at the
relevant level of the organizational structure, (e.g. numbered
containers or central telephone), clarifying whether the sequence
was concealed until interventions were assigned
Randomization – Implementation 10 Who generated the allocation sequence, who enrolled study units and
who assigned study units to their groups at the relevant level
of the organizational structure
Blinding (masking) 11 Whether or not participants those administering the interventions, caregivers
and those assessing the outcomes were blinded to group assignment. If
carried out, how the success of blinding was evaluated. Provide
justification for not using blinding if it was not used
Statistical methods 12 Statistical methods used to compare groups for all outcome(s). Clearly
state the level of statistical analysis and methods used to account for
the organizational structure, where applicable; methods for
additional analyses, such as subgroup analyses and adjusted analyses
Results
Study flow 13 Flow of study units through each stage for each level of the
organization structure of the study (a diagram is strongly
recommended). Specifically, for each group, report the numbers of
study units randomly assigned, receiving intended treatment,
completing the study protocol and analysed for the primary outcome.
Describe protocol deviations from study as planned, together
with reasons
Recruitment 14 Dates defining the periods of recruitment and follow-up.
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Study unit
The term ‘study unit’ refers to the units within the study;
synonyms may be the ‘unit of concern’ or ‘experimental
unit’. Examples of study units may be a hoof, teat, eye,
animal, pen or barn.
Allocation unit
This term refers to the study unit that is randomly allo-
cated to receive the intervention. The allocation unit can
occur at only one level of the organizational structure.
For example, in a swine study evaluating the impact of
a water-based vaccine on weight gain, barns may be
randomly allocated to receive the water-based vaccine or
a placebo; therefore, the allocation unit is the barn. In a
challenge study evaluating the impact of a chilling process
intervention on the prevalence of Campylobacter on poul-
try carcasses, carcass halves may be randomly allocated to
receive either processing method A or B; therefore, the
allocation unit is the carcass half.
Outcome unit
This term refers to the unit at which outcomes are
measured. Common outcomes in livestock production are
weight gain, disease occurrence or the presence or absence
of an infectious disease agent. The outcome unit can occur
at only one level of the organizational structure, and may
be at the same level of the organizational structure as the
allocation unit, or at a lower level. For example, in a swine
study evaluating the impact of a water-based vaccine on
weight gain, barns may be randomized to receive the
intervention; therefore, the unit of allocation is the barn.
If weight gain was measured by weighing all animals in
the pen on a group scale at the end of the study period
(i.e. individual weights are not available), then the out-
come unit is the pen. Alternatively, if weight gain is mea-
sured by weighing each animal individually, then the
outcome unit is the animal, i.e. there are multiple out-
come units within the allocation unit. However, in a chal-
lenge study evaluating the impact of a chilling process on
the prevalence of Campylobacter on poultry carcasses, car-
cass halves may be randomly allocated to receive the inter-
vention. If the presence or absence of Campylobacter is
also measured on carcass halves, then the outcome unit is
the carcass half, which is also the allocation unit.
Primary outcome
The primary outcome refers to an outcome variable of
interest, the expected value of which is used to determine
Table 1. (Continued)
Paper section and topic Item Descriptor of REFLECT statement item
Reported on
page no.
Baseline data 15 Baseline demographic and clinical characteristics of each group, explicitly
providing information for each relevant level of the
organizational structure. Data should be reported in such a way
that secondary analysis, such as risk assessment, is possible
Numbers analysed 16 Number of study units (denominator) in each group included in each
analysis and whether the analysis was by ‘intention to treat’. State the
results in absolute numbers when feasible (e.g. 10/20, not 50%).
Outcomes and estimation 17 For each primary and secondary outcome, a summary of results for each
group, accounting for each relevant level of the organizational
structure, and the estimated effect size and its precision (e.g. 95%
confidence interval)
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, including
subgroup analyses and adjusted analyses, indicating those pre-specified
and those exploratory
Adverse events 19 All important adverse events or side effects in each intervention group
Discussion
Interpretation 20 Interpretation of the results, taking into account study hypotheses,
sources of potential bias or imprecision, and the dangers associated with
multiplicity of analyses and outcomes. Where relevant, a discussion
of herd immunity should be included. If applicable, a discussion
of the relevance of the disease challenge should be included
Generalizability 21 Generalizability (external validity) of the trial findings
Overall evidence 22 General interpretation of the results in the context of current evidence
Text in bold are modifications from the original CONSORT description.
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the study sample size. If researchers have more than one
outcome of interest, the sample size will be determined
by the outcome that needs the highest sample size, and
this will be the primary outcome.
Secondary outcome(s)
This refers to another outcome measure that is poten-
tially equally important but not used to determine the
sample size. There may be more than one secondary
outcome.
Level of organizational structure: The level of organiza-
tional structure refers to the manner in which the
allocation and outcome units are organized within a
production system. The organizational structure may not
always be hierarchical (i.e. not always nested).
Examples of organizational structure
In a swine study evaluating the impact of a vaccine on
piglet mortality, the animals may be at the bottom of an
organizational structure that could include: (1) the pro-
duction company, (2) the site within the production
company, (3) the barn within the site, (4) the pen/room
within the barn, (5) the sow within the room and (6) the
piglet within the sow’s litter. In this example, a hierarchy,
or nested structure, is apparent.
In a feedlot-based cattle study evaluating the impact of
metaphylaxis with an injectable antibiotic on the occur-
rence of respiratory disease in cattle, the cattle may be at
the bottom of an organizational structure that could
include: (1) the originating farm or order buyer, (2) the
receiving feedlot, (3) the truckload and (4) the pen. In
this situation, the nested hierarchy apparent in the piglet
example (see above) does not exist, as different order
buyers may have multiple truckloads, which are mixed in
different pens.
REFLECT Checklist Items
In this section, square brackets ([]) indicate that explana-
tory information has been inserted into the quoted text
by the REFLECT statement authors to clarify the quoted
text. Citations originally included in the quoted text have
been removed to avoid confusion.
Title and abstract
Item 1
How study units were allocated to interventions (e.g.
‘random allocation’, ‘randomized’ or ‘randomly
assigned’). Clearly state whether the outcome was the
result of natural exposure or the result of a deliberate
agent challenge.
Examples
A randomized herd-level field study of dietary inter-
actions with monensin on milk fat percentage in
dairy cows (Dubuc et al., 2009).
Efficacy of a novel trivalent inactivated vaccine
against the shedding of Salmonella in a chicken
challenge model (Deguchi et al., 2009).
Explanation
Citation databases frequently search for citations on the
basis of abstract and title. The inclusion of terms that
include the word ‘random’, such as ‘random allocation’,
‘randomized’, ‘randomization’ or ‘randomly assigned’ in
the title and/or abstract will allow easy identification of
this study design for people conducting electronic data
searches to identify evidence for the efficacy of interven-
tions, and for those conducting systematic reviews.
Further, there are important differences with respect
to the external validity of studies using models of dis-
ease, as occurs in challenge trials, versus natural develop-
ment of the disease, as occurs in field trials, particularly
for infectious diseases. Challenge trials are often con-
ducted under controlled experimental conditions, with a
single pathogen in a restricted population. Consequently,
the external validity of the challenge study may not com-
pare favourably with the same trial conducted under
commercial conditions using a natural disease exposure.
Therefore, the identification of a trial as having used
natural or deliberate exposure allows for the rapid differ-
entiation of these studies. We strongly encourage the use
of the term ‘field trial’ or ‘clinical trial’ to describe stud-
ies associated with natural development of the disease
and the term ‘challenge study’ or ‘challenge trial’ or
‘challenge model’ for studies that use induced models of
disease.
Introduction
Item 2
Scientific background and explanation of rationale.
Example
The success of commercial dairies depends on a reli-
able supply of healthy replacement heifer calves with
good genetic potential for milk production. Several
management practices have been recommended to
producers for reducing the frequency of calf
morbidity and mortality on dairy farms. One area
commonly emphasized is the calving pen. The
The REFLECT Statement: Elaboration J. M. Sargeant et al.
110 ª 2010 Blackwell Verlag GmbH • Zoonoses Public Health. 57 (2010) 105–136
management of calving pens influences the degree
of early calf exposure to infectious environmental
pathogens (Pithua et al., 2009).
Explanation
The introduction should provide sufficient contextual
background, as it relates to the study topic, to provide
the reader with a basic understanding of the underlying
science upon which the study was based. This should
include a description of the nature, scope and extent
or magnitude of the problem under study; the patho-
physiological basis for active components in the pro-
posed treatment or the justification for considering a
new treatment regimen when there is an existing treat-
ment, as well as any other factors known to influence
the outcome and interpretation of data for the study
topic.
Authors should indicate whether the intervention is
directed at a single component or multiple components
associated with the aetiology of the naturally occurring
disease. For instance, challenge trials or field trials may
test the efficacy of an intervention against specific bacte-
ria, whereas natural development of the disease may be
associated with multiple organisms. Providing this infor-
mation in the introduction provides the reader with the
context necessary for the interpretation of the study
results.
The introduction section should also provide a ratio-
nale justifying the need for the research. This may include
an identification of knowledge gaps, as well as an
indication as to how the current study will enhance our
knowledge in the topic area. The authors should provide
an overview of the current state of knowledge, based on
other published studies. If available, the authors should
reference any systematic reviews completed for the
same or related interventions. The CONSORT statement
(Moher et al., 2001d) suggests that for some human dis-
ease processes, a formal review of the published literature
may be the preferred course of action over carrying out
another (unnecessary) primary study. In livestock species,
there is a paucity of primary studies for many interven-
tions, and systematic reviews are not yet commonly used
(Sargeant et al., 2006).
Many veterinary and food-safety journals prefer that
the specific objectives be included in the final paragraph
of the introduction section. In the CONSORT statement,
the objectives were described in Item 5 in the methods
and materials, and the REFLECT statement left the item
relating to the study objectives as Item 5, although we
recognize that the introduction often will be an appropri-
ate place for this information.
Methods
Item 3
Eligibility criteria for owners/managers and study units at
each level of the organizational structure, and the settings
and locations where the data were collected.
Examples of eligibility criteria
Study farms were initially identified through private
veterinary practices (PVP), which had submitted any
kind of cattle samples for diagnosis to the Veterinary
Laboratories Agency’s regional laboratories (VLA RL)
during the previous 12 months as previously described.
The cattle farms within each PVP, who submitted the
largest number of samples in the previous year, were
included and further suggestions of potentially inter-
ested farmers from the PVP were also accepted. Neigh-
bouring farms were excluded. A total of 411 farms
distributed throughout England and Wales were con-
tacted by phone to assess willingness to participate in
the study and eligibility of the herd by questionnaire.
Farms were eligible, if they retained more than 60 cattle
including 20 young stock, had a bovine tuberculosis-
negative status, and the premises were not shared with
any public access enterprises such as open farms, Bed &
Breakfast or farm-shops including selling unpasteur-
ized milk (Ellis-Iversen et al., 2008).
Animals that arrived at the feedlot between Octo-
ber16, 1994, and December 13, 1994, were candidates
for the trial. In this study, the case definition for UF
[undifferentiated fever] was an elevated rectal tem-
perature (>40.5C) and a lack of abnormal clinical
signs referable to organ systems other than the respi-
ratory system within 3 wk after arrival at the feedlot.
Exclusion criteria were moribund animals and
animals with a previous treatment history for any
disease (Jim et al., 1999).
Explanation
All trials address an issue relevant to a population of
interest, i.e. the target population; however, for logistic
reasons, trials use eligibility criteria to define a study
population. Study unit selection on the basis of eligibility
criteria may lead to meaningful differences between the
target population and the study population; therefore,
these eligibility criteria must be stated explicitly to enable
the reader to assess differences between the study and tar-
get populations, and ultimately to assess external validity
of findings. It is not necessary to describe both eligibility
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and exclusion criteria, as study units that do not fit the
eligibility criteria are excluded.
In the human medical field, this item generally relates
to eligibility criteria for participants and restriction of the
trial setting to one or more medical centres (Altman
et nbsp;al., 2001). In livestock trials, the concept of
‘participant’ refers to the owner or manager of the
animals who consents to participate in the trial. Thus, it
is important to report eligibility criteria of the owner/
manager and also eligibility criteria for the study units.
Livestock studies frequently need to consider multiple lev-
els of organizational structure when the study units are
enrolled. For example, for evaluation of the efficacy of
swine vaccines, the following are usually enrolled: owners
of the facilities, barns within the facilities, pens within the
barns and finally pigs within the pens. Decisions made
about eligibility criteria at each organizational level may
influence differences between the study population and
the target population, and should be reported.
Frequently, the only determinant of eligibility for a
facility may be a personal relationship with the researcher
or a veterinary practice and willingness to co-operate by
the owners/managers, or the proximity to the researchers’
laboratories. If such convenience sampling is used, this
should be stated. In other situations, facilities may be
selected randomly from a sampling frame, such as a pre-
mises identification database or livestock commodity
organization or program list. In some instances, farms
may be selected on the basis of the presence or frequency
of occurrence of the disease of interest.
At the study-unit level, eligibility criteria commonly
include age or production stage, sex, co-morbidities or
previous treatments. For example, it is common for live-
stock-production trials to exclude study units with a prior
history of the disease of interest, i.e. excluding animals
with an existing antibody titre to a specific pathogen in
trials that are evaluating the efficacy of a vaccine to pre-
vent illness caused by that pathogen. In challenge studies,
it is common that only animals not colonized by the
pathogen of interest are eligible for the study, i.e. swine
colonized with Salmonella may be excluded from a study
planning to use an artificial challenge with Salmonella.
Examples of setting and location information
The experiment was carried out in a mountainous
area (1,000 m above sea level) in the northwest of
Spain (653¢W, 4321¢N; Sierra de San Isidro, Illano,
Asturias), where shrubby heather-gorse vegetation is
dominant. Four plots of 5000 m2 each were estab-
lished, in which the vegetation had been improved
in 2001 by soil ploughed and dressing and sowing
perennial ryegrass (Lolium perenne L.) and white clo-
ver (Trifolium repens L.), and removing any heather
that was present. Annual rainfall in the experimental
year (2004) was 1,589 mm. During the grazing sea-
son, mean rainfall ranged from 36 to 111 mm/mo.
Mean average temperatures were 17.3-C in June
and 10.6-C in May (Osoro et al., 2007).
Broiler chicks were hatched from commercially
obtained eggs and grown to market age (56 to 63 d)
on pine shavings in floor pens (5 · 8 m) in a con-
trolled environment-type house.…All broilers were
processed in the pilot plant processing facility at the
Russell Research Center (Northcutt et al., 2006).
The setting and location may affect the external validity
of the study. For some diseases, it may be relevant to
report the geographical location(s) where the trial was
conducted, as the frequency of many livestock diseases
and the response to interventions varies geographically as
a result of differences in climate and management sys-
tems. The time of year when the study was conducted
may also be relevant to disease frequency. When report-
ing time of year, the month(s) and year should be
included, and the reader should be allowed to infer the
season.
At the farm level, issues related to setting that could
influence the external validity of the study should be
described. Authors should describe the group sizes for all
relevant levels of the organizational structure, i.e. the
capacity of the facility and the number, size and capacity
of barns/pens/cages, etc., used to house study units. Feed
and other pertinent management details and the presence
or absence of the disease of interest, or other endemic
diseases, should also be described. The nature of the man-
agement of the facility should also be reported. As an
example, there may be differences in facility management
between a commercial operation of a large company; an
independent, privately owned facility and a facility oper-
ated by a university or government research organization.
Item 4a
Precise details of the interventions intended for each
group, at the level at which the intervention was
allocated, and how and when interventions were actually
administered.
Example
Treatment was assigned at the heifer level within
herd. Each heifer was randomly assigned to a treat-
ment using a random number generator function (R
Development Core Team, 2006), and the farmers
were blinded to the treatment. Before treatment,
each teat-end was scrubbed with a cotton wool
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pledget moistened in 70% methanol and a gland
secretion sample was collected aseptically (n = 4,268
glands). No secretion was discarded before collection
because there was only a small total volume of secre-
tion present in most glands. If no secretion could be
collected from a gland, it was recorded as a missing
sample (n = 99 glands). Following sampling, all 4
glands within a heifer were infused with 2.6 g of bis-
muth subnitrate following teat-end scrubbing
(n = 268 heifers; Teat Seal, Pfizer Animal Health NZ
Ltd., Auckland, New Zealand), or a heifer was
administered with 5 g of tylosin base i.m. for 3 d at
24-h intervals (n = 268 heifers; Tylan 200, Elanco
Animal Health, Manukau City, New Zealand), or all
4 glands were infused with the teat sealant and the
heifer was administered 5 g of tylosin base i.m. for 3
d at 24-h intervals (n = 266 heifers), or they were
left as an untreated control (n = 265 heifers). The
tip of the teat sealant cannula was inserted
approximately 3 mm into the teat canal for infusion.
Following sampling or infusion, 0.5% effective iodine
was applied by manual spraying to all teat ends.
Technicians administered the first treatment of tylo-
sin and then left labeled doses of tylosin for the
remaining 2 treatments for farm staff to administer
(Parker et al., 2008).
Explanation
The description of the intervention(s), including the con-
trol intervention, should be provided in sufficient detail
to allow the reader to replicate the intervention. Phrases
such as ‘applied per labelled instructions’, ‘as per manu-
facturers’ instructions’, ‘standard industry practices’ or
‘routine treatment’ do not constitute an adequate descrip-
tion that can be replicated. Differences in management or
handling among intervention groups should be included
in the description of the interventions.
The unit of allocation for the intervention(s) should be
clearly stated, and this unit must correspond with the
unit of randomization. Examples of phrases to be used
include ‘the barn was randomly allocated to receive either
treatment A or treatment B’, ‘the site was randomly allo-
cated to receive either treatment A or treatment B’ or ‘the
teat was randomly allocated to receive either treatment A
or treatment B’. These phrases will eliminate confusion
often associated with current descriptions. The intent is
to state clearly the unit of allocation with adequate detail,
so that there is no ambiguity for the reader of the trial
report.
For pharmaceutical interventions, the minimum
description should include the compound name, the con-
centration, the dose, the delivery matrix and the route
and the frequency of administration.
For biological interventions such as vaccinations, the
minimum description should include the organism(s) and
whether each one is a modified-live or killed product,
substance or probiotic unit; the adjuvant; the concentra-
tion per ml (if known); the dose; the delivery matrix and
the route and the frequency of administration.
For surgical interventions, the minimum description
should include the training level of the person adminis-
tering the procedure, the number of people administering
each procedure, the prior number of times the person
had performed the procedure and the post-operative care,
including the use of other post-operative treatments such
as antibiotics or medications for alleviation of pain. For
example, a field trial comparing surgical versus toggle
(non-surgical) repair of a left-displaced abomasum repair
should include a complete description of the surgical
procedure, including post-operative care and how that
care differed from the post-operative treatment of cases
receiving toggle intervention. For a surgical intervention,
it is important to include who performed the procedure,
as a procedure performed by farm staff versus a veterinar-
ian may represent different interventions.
For food-processing interventions, the minimum
description should include the production process and
variables that may affect the outcome of that process. For
example, an intervention assessing chlorine concentrations
during immersion chilling in a poultry plant should
describe the volume of water per carcass, the water
refresh rate, the water pH, the water temperature, the
water hardness, available chlorine versus total chlorine
concentration, the source of the chlorine and the length
of time of carcass immersion for each intervention.
It is also preferable to state clearly whether treatments
groups are similar, instead of leaving it to the reader to
assume that the groups are the same with respect to other
factors that could affect the outcome. For example, in a
feedlot trial assessing the pen-level prevalence of Escheri-
chia coli 0157 in pens that received probiotic A compared
with probiotic B at arrival, it is preferable to state clearly
that all animals received the same ration or water from
the same water supply, if ration or water supply are
thought to impact E. coli 0157 prevalence.
If the intervention was applied to individual animals,
the authors should state whether the animals were individ-
ually housed or housed in a group, and if so, the number
per housing group. If the intervention was applied at the
group level, the authors should clearly state the number of
animals per group. The description of housing of the
allocation units should correspond with the levels of the
organizational structure described in Item 3.
J. M. Sargeant et al. The REFLECT Statement: Elaboration
ª 2010 Blackwell Verlag GmbH • Zoonoses Public Health. 57 (2010) 105–136 113
Information about the housing of the allocation units
should be described, as this information is essential for
assessing the appropriateness of the statistical analysis and
the external validity of the study. This information will
also further clarify whether the study was a field trial
under normal production conditions, a field trial using
small numbers of animals per pen (as is common in trials
conducted in research herds) or a controlled study under
laboratory conditions.
In some challenge trials, non-challenged animals are
included to serve as negative controls. When this is a fea-
ture of the trial, the number of negative controls and
their housing relative to the study units (i.e. within
challenged groups, or proximity to, and opportunity for
contact with, challenged animals) should be described.
Item 4b
Precise details of the agent and the challenge model, if a
challenge study design was used.
Examples
A mixture of three E. coli O157:H7 strains resistant to
50 g mL–1 nalidixic acid was used as inoculum for the
experiment with sheep. The mixture contained E. coli
O157:H7 strains E32511 and E318N (human isolates),
and H4420nal (bovine isolate). The three strains were
cultured individually in tryptic soy broth for 18 to
24 h at 37C (200 rpm). The optical density (OD640)
was measured to ensure approximately equal cell den-
sity of all cultures. Aliquots (4 ml) of each strain were
pooled with 13 ml of sterile PBS (pH 7.4) in sterile
60-mL polypropylene containers. Subsamples were
serially diluted in PBS and enumerated by plating
100 ll aliquots in duplicate onto sorbitol MacConkey
agar amended with cefixime (50 mg L–1), potassium
tellurite (2.5 mg L–1) and nalidixic acid (50 lg ml–1),
denoted CT-SMACnal.... Feed was withdrawn 48 h
before inoculation to promote establishment of the
inoculated E. coli O157:H7 in the gastrointestinal
tract. On day 0, each sheep was orally inoculated
with 1010 CFU of the three-strain mixture of E. coli
O157:H7 using a 60-mL syringe connected to a
polypropylene orogastric tube. The inoculum was fol-
lowed by two 60 mL aliquots of sterile PBS to rinse
the syringe and tubing. Faecal samples were collected
from each animal on day 1, to confirm shedding of
nalidixic acid-resistant (nalR) E. coli O157:H7 (Cook
et al., 2005).
The animals were divided into 2 groups of 12 cows
each (6 pairs per group) that went through the pro-
tocol 4 wk apart. The duration of the experimental
period was 17 d. From d 0 to 6, cows were fed a
standard diet based on a forage mix with 50% alfalfa
silage (42% NDF and 21% CP on a DM basis) and
50% corn silage (38% NDF and 9% CP on a DM
basis) fed ad libitum, and offered twice a day, at
0730 and 1500 h. Nutrient composition of forage
was determined on a 6500 NIR spectrophotometer
(Foss in North America, Eden Prairie, MN) using
equations of the NIRS Consortium. Vitamins and
minerals were fed to meet requirements, mixed with
1.4 kg of corn-based concentrate. Vitamins repre-
sented 1.0% of the DM of the concentrate (3,304 IU/
g of DM of vitamin A, 1,101 IU/g of DM of vitamin
D, and 55 IU/g of DM of vitamin E) and minerals
represented 0.6% of the DM of the concentrate
(0.55% Mn, 0.55% Zn, 0.35% Fe, 0.14% Cu, 0.008%
I, 0.006% Se, and 0.002% Co). On d 7, cows were
restricted to 30% of the energy required for preg-
nancy and maintenance by restricting the intake of a
forage mix, based on equal proportions of alfalfa
silage, corn silage, and wheat straw that was offered
once a day in the morning in addition to the 1.4 kg
of concentrate previously described. Wheat straw
analysis indicated a CP content of 3.5% and 77%
NDF (Cooke et al., 2007).
Explanation
The precise details of the challenge model used in the
study are critically important for assessing the external
validity (Item 21). Challenge trials represent an enor-
mously broad spectrum of conditions. Often, challenge
trials involve exposure to infectious agents. These models
of disease may not always be associated with clinical dis-
ease; for example, challenge models of foodborne patho-
gens rarely induce clinical disease. Other models may not
have an infectious component, such as lameness models
or models of metabolic disease, such as fatty liver in dairy
cattle. The onus is on the authors to provide sufficient
details of the model used in the challenge trial to enable
the reader to assess its validity as a model for the ‘real’
condition.
It is not possible to provide guidelines that adequately
describe all possible models. However, for an infectious
model, it is recommended that the following be included:
1 The timing of challenge relative to intervention, i.e. X
h prior to initiation of the intervention (for therapeutic
interventions), or X h after the intervention (for preven-
tive interventions). The length of any acclimation period
should be included.
2 The organism used, including the source,
sequence information and passages. A statement as to
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whether it is heterologous or homologous with the
biological intervention.
3 The concentration of organism per unit of delivery
matrix should be included, e.g. 2*106 CFU per ml or per
g. It is critical that the units of concentration and the
delivery matrix are each specified. For organism chal-
lenges, the physiological state of the challenge organ-
ism(s) may be relevant and, as this may be influenced
by the initial cultivation techniques, the details of culti-
vation and preparation prior to inoculation must be
included.
4 Dose and route of delivery matrix administered, e.g.
the challenge organisms were mixed with 100 ml whole
milk administered per os.
5 The total amount of organism received, which is a
function of #3 and #4. This is included as a means of
checking the dose to ensure that they match.
6 The source of the isolate used in the challenge inocu-
lum should be described, e.g. clinical isolate from a pig
with diarrhoea, strain X from Y collection, Nth passage of
virus from cell culture.
Item 5
Specific objectives and hypotheses. Clearly state primary
and secondary objectives (if applicable).
Example
The primary objective of this study was to investigate
if eprinomectin treatment of adult dairy cows
around calving had any beneficial effects on the
calving to first insemination interval, calving to con-
ception interval, and number of inseminations per
conception in herds with no or limited pasture
exposure. The secondary objective was to investigate
whether bulk milk ODR [optical density ratio] could
be used to identify herds whose calving to
conception interval could benefit from eprinomectin
treatment (Sithole et al., 2006).
The objective of this study was to compare calf mor-
bidity, mortality, and weight gain in preweaned
calves reared with and without antibiotics for ther-
apy and prophylaxis. The study hypothesis was that
calf weight gain, morbidity, and mortality are not
affected by antibiotics in the milk replacer or given
as individual therapy (Berge et al., 2005).
Explanation
The authors should state the objectives introduced in
Item 2 and the corresponding null hypothesis to be
tested. Objectives (or aims) are the concepts that studies
are designed to investigate. An objective usually states a
broad goal to help direct the study. Hypotheses, although
similar in concept, specifically state what the study is set-
ting out to support, and allow the researcher to test a
proposed hypothesis statistically. Authors should state the
null hypothesis to be tested. This documents how the
authors intend to achieve the objective and removes an
uncertainty about the purpose of the research. Some stud-
ies are conducted to show superiority of an intervention,
in which case the null hypothesis should be that the treat-
ments are the same with respect to the primary outcome.
Other studies are designed with the purpose of showing
equivalence or non-inferiority of an intervention, in
which case the null hypothesis is usually that the treat-
ments are different with respect to the primary outcome
(Jones et al., 1996). There is indication that although
some studies are conducted with the objective of assessing
equivalence, the null hypothesis is framed as for superior-
ity studies (O’Connor et al., 2010f). By stating the null
hypothesis clearly, the author will clarify the purpose of
the research. This will enable the reader to interpret the
meaning of non-significance correctly. This information
will also allow the reader to ascertain if the sample size is
correctly determined and whether the statistical methods
are appropriate. If a one-tailed hypothesis test is used,
then published studies justifying a unidirectional treat-
ment effect should be referenced. If there are multiple
objectives, authors should characterize them as primary
versus secondary and consider ranking within the catego-
ries relative to their importance to the study’s focus.
Item 6a
Clearly defined primary and secondary outcome measures.
Example
The primary outcome was IBK [infectious bovine
keratoconjunctivitis] cumulative incidence over the
study period. The secondary outcome was weaning
weight (Funk et al., 2009).
Explanation
All trials measure at least one outcome and compare this
between intervention groups. The outcomes selected for a
trial need to be linked to the objectives and hypotheses.
All outcomes should be identified and defined, and the
methods used to measure each outcome should be
described. If disease status is used as an outcome, a case
definition should be provided, and person(s) responsible
for assigning that diagnosis should be identified (e.g.
owner/manager versus veterinarian). If specific diagnostic
tests contribute to the assessment of the outcome, sensi-
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tivity and specificity estimates should be included, as well
as a justification of why these values are applicable to the
study population. Sufficient information should be pro-
vided so that the study could be duplicated, e.g. details
such as whether blood samples were collected from a coc-
cygeal vein versus a jugular vein. If a standard approach
is modified, describe the modification, rather than using
phrases such as ‘… with slight modification’.
The primary outcome refers to the measure used to
determine the study sample size (Item 7). Other outcome
measures, which may be potentially equally important, but
were not used to determine the sample size, should be
referred to as secondary outcomes. The rationale for differ-
entiating the outcomes as primary and secondary is to
allow the reader to understand for which outcomes the
study had sufficient power to detect meaningful differences
in effect. In livestock trials, it is common to have one out-
come related to the disease of interest (e.g. mortality or
morbidity) and one related to performance (e.g. average
daily gain), as these indices are often of primary concern to
livestock owners. In situations where two outcomes are
truly of interest and the study is designed to have sufficient
power for both outcomes, the authors should provide sam-
ple size information for both outcomes (Item 7) and
describe the outcome that needs the highest sample size as
the primary outcome. When an outcome is measured at
multiple times/points, the authors should specify which
time point is the primary outcome. Secondary outcomes
may also be unanticipated or unintended outcomes that
become apparent as the study progressed, and it should be
stated that these were unplanned outcomes.
The use of multiple outcomes is common in trials con-
ducted in livestock populations. In a review of trials of
antibiotic therapy for bovine respiratory disease, 25 of 35
studies reported multiple outcomes, and none indicated
the primary outcome (O’Connor et al., 2010f). In a study
evaluating reporting in food–animal trials with health or
production outcomes, 91 of 100 trials reported multiple
outcomes, with only four trials identifying the primary
outcome (Sargeant et al., 2009a). Of 100 pre-harvest
food-safety trials evaluated in a similar study, 91 reported
the use of multiple outcomes, with none of the trials
identifying the primary outcome (Sargeant et al., 2009b).
Item 6b
Where applicable, any methods used to enhance the
quality of measurements (e.g. multiple observations and
training of assessors).
Example
Corneal ulcers in the digital photographs were traced
on a computer tablet (Wacom Cintiq 15X LCD
tablet, Wacom Technology Corporation, Vancouver,
WA, USA) using public domain image analysis
software (ImageJ program; available at http://
rsbweb.nih.gov/ij). Differences in magnification were
accounted for by standardizing the scale of each
tracing using the ruler in each photograph. The
mean of three tracings of each ulcer was used to cal-
culate the corneal ulcer surface area measurement;
for data analysis, the square root of the corneal ulcer
surface area was used to represent the ulcer surface
area measurement (SAM). The limit of detection was
0.008 cm2, an area corresponding to a 1-mm diame-
ter circle. Ulcers that appeared linear or stellate were
considered to be the result of mechanical trauma
and were not counted as ulcers associated with IBK
unless the ulcer was still present at the next weekly
observation (Angelos et al., 2007).
Means of bacterial populations (log10 CFU/g) from
each treatment were calculated from three replications
for each experiment (Fabrizio and Cutter, 2005).
Explanation
Authors should provide details of any steps used to
increase the precision or validity of an outcome measure.
For instance, use of repeated measurements of an out-
come or multiple samples may be used to define the out-
come status of a study unit. The description should
include the number of observations and the means of
summarizing the outcome.
Standard guidelines used regarding quality of measure-
ments should be specifically cited where relevant. Limits
of detection, precision of measurements and cut-off
points should always be described. When applicable,
referencing validated scales and consensus guidelines is
recommended to ensure transparency and reproducibility.
For determination of bacterial or viral outcomes, standard
procedures should be used, if available, or deviations from
standard procedures should be justified. Resources for
such standards are available for many areas. For example,
standards for culture of mastitis pathogens in bovine milk
are provided by the Clinical and Laboratory Standards
Institute and National Mastitis Council (National Mastitis
Council, 1987; Thompson Reuters, 2009).
Authors should provide details on any formal study-
specific training of the outcome assessors, including
details of inter-rater agreement during training or pre-
testing. This is especially important for subjective out-
comes, e.g. lameness, pain, body-condition scores and
physical appearance. Many livestock studies use producer-
based diagnoses of diseases, and if no additional training
was provided, this should be stated.
The REFLECT Statement: Elaboration J. M. Sargeant et al.
116 ª 2010 Blackwell Verlag GmbH • Zoonoses Public Health. 57 (2010) 105–136
Item 7
How sample size was determined and, when applicable,
explanation of any interim analyses and stopping rules.
Sample size considerations should include sample size
determinations at each level of the organizational
structure and the assumptions used to account for any
non-independence among groups or individuals within a
group.
Examples
A sample size of 699 animals in each group was
calculated to have an 80% power to detect a differ-
ence in means of 1.5 kg, assuming that the common
standard deviation was 10 kg using an anova with a
consecutive two group t-test and a 5% two-sided sig-
nificance level. For compensation of possible drop
outs a total of 1542 healthy piglets from three
consecutive farrowing batches, each comprising
approximately 500 animals were included into this
study (Fachinger et al., 2008).
Sample sizes were calculated by a multi-level
approach with design-effects and intra-class correla-
tions deducted from variance between [faecal] pats,
groups, and farms observed in a previous field study
on a similar population. The required samples sizes
were 48 control farms and 48 farms in each interven-
tion group to detect a risk ratio of 5 at 80% power
with 95% confidence, when using a design effect of
13.22 to adjust for a group cluster size of 20 pat
samples per group per visit. The design effect was
estimated from data originating from a longitudinal
study using the same sampling approach along with
individual animal sampling (Ellis-Iversen et al.,
2008).
Explanation
Use of an adequate sample size to detect treatment differ-
ences that are economically and biologically important is
fundamental to sound trial design. The main statistical
considerations in sample size calculation are the magni-
tude of the effect size (e.g. difference in proportions,
means, survival times, etc.), standard deviation of the
outcome, power (1-b [type II error] = probability of
accepting the null hypothesis when it is not true) and the
significance level (a = type I error = the probability of
rejecting the null hypothesis when it is true). Typically,
power and significance values of 80% and 5%
respectively, are used in calculations. The effect size that
can be detected is inversely related to sample size – the
smaller the difference, the larger the group sizes. The
most common problem is lack of adequate sample size,
although use of more animals than is necessary is also an
important ethical concern.
For the null hypothesis and primary outcome
identified in Items 5 and 6, authors should describe how
the sample size was determined for each level of the
organizational structure of the study setting. The descrip-
tion should include how non-independence of the out-
come measurements and exposure were accounted for in
the calculations, if relevant. If the study has multiple
outcomes, and the study size chosen was considered ade-
quate to detect clinically important differences for several
outcomes, this should be reported, and the assumptions
used to reach this conclusion for each outcome should
be described.
Authors should state the basis for assumed values of
the outcomes in the treatment groups, citing published
studies whenever possible. For example, a 10% absolute
difference in cumulative incidence could occur if the trea-
ted and untreated groups had incidences of 10% and 0%
or 50% and 40% respectively, but the sample size
required to detect the latter scenario would be greater.
In trials with long-term follow-up in production ani-
mal systems, there can be substantial loss to follow-up.
For example, in a 3-year follow-up study of 100 cows in
a dairy herd with 30% annual culling, only 33 of the orig-
inally enrolled cows would be expected to remain. How
the anticipated loss to follow-up was accommodated
should be described in later items (Items 13, 16, 20 and
21), as this may have a large effect on internal validity.
Sample size should not be confused with the specimen
size. Sample size (the number of study units) and speci-
men size (e.g. use of 10 g of faeces versus 25 g of faeces
for laboratory culture of enteric pathogens) have distinct
meanings. Specimen size should be included in Item 6
(description of the outcome measures).
Example of stopping rules (from the human-health
literature)
Primary end points were progression free survival,
response rate, and toxicity. Overall survival was a
secondary end point. Two analyses were initially
planned. The first analysis was to assess and compare
response rates after 21 patients were recruited to
each group. If one of the groups had had a response
rate less than 10% and if a difference greater than
15% in response rate was observed between the two
groups, the study would have been stopped. If not,
the trial could continue as a phase III study. The
final planned sample size was then 91 patients in
each group, on the basis of detection of a 15% dif-
ference in progression free survival between the two
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arms (15% v 30% at 1 year) with a two sided test,
an alpha risk of 5%, and a power of 80% (Negrier
et al., 2000)
Explanation
The consensus meeting members were unaware of any
livestock studies with production, health or food-safety
outcomes that reported trials using stopping rules. There-
fore, no examples from this literature could be provided,
and the explanation for this item is quoted from the
example used in the CONSORT statement elaboration
document.
There are many situations where stopping rules may be
applicable or useful in livestock production, and further,
there are probably many published situations where
authors take ‘looks’ at the data before the end of the
study. It is not uncommon for clinical trials to recruit
study units sequentially on the basis of the availability of
specific inclusion criteria and in some instances,
recruitment may occur over a long period of time. If an
intervention is particularly efficacious, or if it causes
harm, it may be ethically appropriate to end the trial
early. Trials stopped early for harm should result in dis-
continuation or decreased use of potentially harmful
interventions, and trials stopped early for benefit should
contribute to earlier market availability of efficacious
treatments. In the human healthcare literature, RCTs
stopped early for benefit are becoming increasingly
common (Montori et al., 2005). However, this decision
requires that the data be examined at one or more time
points during the course of the trial. This raises statistical
concerns, because the multiplicity of testing increases the
probability of a type I error and the identification, as sig-
nificant, of random fluctuations towards greater treatment
effects (Schulz and Grimes, 2005). In an example pro-
vided in the original CONSORT elaboration document, if
accumulating data from a trial were examined at five
interim analyses, the overall false-positive rate would be
nearer to 19% than to a nominal 5% (Altman et al.,
2001). Statistical methods are available for stopping pro-
cedures (Schulz and Grimes, 2005), and their use should
be pre-specified in the trial protocol if interim analyses
are planned. These methods generally make use of a small
P-value to aid in decision making or for use as a formal
stopping rule (Altman et al., 2001). The decision to stop
trials early is controversial; a systematic review of trials
stopped early for benefit reported implausibly large treat-
ment effects, particularly when the number of events was
small (Montori et al., 2005). An extension of this review
is ongoing to further understand the extent to which
trials stopped early may exaggerate treatment effects (Briel
et al., 2009).
Item 8
Randomization (sequence generation). Method used to
generate the random allocation sequence at the relevant
level of the organizational structure, including details of
any restrictions (e.g. blocking and stratification).
Example
Each heifer was randomly assigned to a treatment
using a random number generator function (R
Development Core Team, 2006)…. (Parker et al.,
2008).
Explanation
Randomization is essential to internal validity, as it is
designed to minimize differences between the treatment
groups and can be implemented in most RCTs, regardless
of level of intervention allocation. Study units should be
assigned to groups on the basis of chance (i.e. a random
process), to limit the potential for confounding to
influence the study result or for selection bias in the
assignment of study units to treatment groups. The term
‘random’ has a precise meaning, wherein each study unit
has a known probability of receiving a given treatment
prior to assignment of the treatments. The actual treat-
ment that a specific study unit is allocated is determined
by a chance process and cannot be predicted. The meth-
ods used to generate the random allocation sequence
should be reported in sufficient detail to allow the reader
to assess the likelihood of bias in group assignment.
Many methods of sequence generation are adequate.
However, readers cannot judge the adequacy from such
terms as ‘random allocation’, ‘randomization’ or ‘ran-
dom’ without further elaboration. Therefore, authors
should specify the method of sequence generation, such
as a random-number table or a computerized random-
number generator.
Deterministic allocation methods, such as alternate ani-
mal identification numbers, days of the week, date of
birth, birth order and gate cutting, are not random
(Schulz and Grimes, 2002). When these methods are
used, they should not be described using the term ‘ran-
dom’ or any variation of it. There is evidence in trials
involving livestock that the term ‘random’ is misused to
describe non-random processes, e.g. process such as gate
cutting (O’Connor et al., 2010f).
When authors do not use random methods to allocate
study units to treatment groups, the method of allocation
should be described in a manner that would allow the
reader to determine if bias was likely to be introduced
because of the lack of randomization. The use of terms
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such as ‘systematic randomization’ and ‘quasi randomiza-
tion’ to describe these methods of allocation is not appro-
priate without further elaboration.
Often there are valid reasons to avoid simple randomi-
zation and to employ instead a restricted randomization
method. The description of restrictors on randomization
are provided in the ‘CONSORT statement: Explanation
and Elaboration’ document and other references (Chow
and Liu, 1998; Altman et al., 2001). Block randomization,
also called permuted block randomization (Chow and
Liu, 1998), is a method of allocation that ensures an
equal distribution of study units to intervention groups
and is often employed when the study size is small. The
approach is to divide the whole series of study units into
several blocks with equal or unequal size and randomly
allocate animals to treatment within blocks, e.g. in a
study of 32 animals, there may be eight blocks of four
animals each. In challenge studies, which often have small
study sizes, consideration should be given to employ
block randomization. One disadvantage of block random-
ization is the potential for someone to deduce the
intervention if they are aware of the block size. This risk
can be mitigated by varying the block size randomly, i.e.
blocks of two, four and six, within a study. An excellent
description of how to implement block randomization is
available (Altman and Bland, 1999). Block randomization
may also be useful for field studies with group-level units
of allocation, such as pen-level studies. In a pen-level
study comparing two treatments with 20 pens per treat-
ment, it may be sensible to use 10 blocks of four pens
each to ensure that every group of four pens enrolled has
two treated and two untreated pens (Chow and Liu,
1998).
Stratified randomization includes a covariate (thought
to be a confounder) in the allocation sequence determina-
tion. For example, a feedlot study may stratify by heifers,
bulls and steers, and use block randomization within each
stratum to allocate to treatment group, or a swine study
may control for the effect of sow and weight using strati-
fied randomization, e.g. piglets ordered by weight from
the heaviest to the lightest within a litter (a sow) and
allocated to treatment in blocks of two piglets. Stratified
randomization requires that block randomization be used
within the strata to ensure balance of treatments within
strata (Altman and Bland, 1999).
Minimization may also be used with small sample size
trials to minimize differences between groups with respect
to important prognostic or confounding variables. In this
approach, the first study unit is assigned to treatment
group using a random method; thereafter, allocation to
treatment group is based on minimizing the differences
among groups based on the pre-selected factor(s) (Trea-
sure and MacRae, 1998).
Item 9
Randomization (allocation concealment). Method used to
implement the random allocation sequence at the relevant
level of the organizational structure (e.g. numbered con-
tainers), clarifying whether the sequence was concealed
until interventions were assigned.
Example
Sealed envelopes numbered 1 through 120 were
prepared that assigned each cow to the laparoscopy-
assisted abomasopexy or control group. These
envelopes were opened only after confirmation
of eligibility and immediately before surgery (Seeger
et al., 2006).
The remaining 57 farms were randomly allocated
into three intervention groups and one control
group…. The allocation was done blindly by a clerk,
who assigned each participating farm a random letter
drawn from an envelope, which contained one letter
for each intervention group and … for the control
group (Ellis-Iversen et al., 2008).
Explanation
Authors should describe whether or not any steps were
taken to conceal allocation sequence until after the study
unit was enrolled. The aim of allocation concealment is
to prevent bias at the recruitment/enrolment phase of the
trial. In a trial with adequate allocation concealment,
informed consent should be obtained from the owner/
manager, and the decision to include or exclude a specific
study unit in the trial should be made with no knowledge
of the next intervention group assignment in the alloca-
tion sequence. There is empirical evidence in the human
healthcare literature that failure to report allocation con-
cealment is associated with exaggerated treatment effects
(Schulz et al., 1995; Kunz and Oxman, 1998; Moher
et al., 1998; Juni et al., 2001; Kjaergard et al., 2001). Allo-
cation concealment differs from blinding, which aims to
prevent misinformation bias in the measurement of the
outcome and differential management of treatment
groups, and is implemented after allocation to the
intervention.
An example of bias introduced as a result of failure to
conceal the allocation sequence may occur in a feedlot.
For example, the processing crew at a feedlot may decide
not to enrol a truckload of high-risk cattle into the study
if they have an unfavourable view of the treatment that
truckload will be allocated. Concealment of the treatment
to be received until after the cattle have been enrolled
would prevent the introduction of such a bias. Similarly,
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in a dairy cattle study, the owner/manager may wish cer-
tain cattle to be assigned to the treatment group because
of their genetic value or severity of disease. If the person
implementing the allocation sequence is unaware of the
next assignment, the person is not able to be consciously
or unconsciously influenced by the owner’s preference.
Currently, it is not common for livestock studies to use
formal allocation concealment. However, inadequate allo-
cation concealment can subvert the random allocation
process (Schulz and Grimes, 2002).
Item 10
Randomization (implementation). Who generated the allo-
cation sequence, who enrolled study units and who
assigned study units to their groups at the relevant level
of the organizational structure.
Example
Prior to the ISU [Iowa State University] farm visits,
containers holding the autogenous vaccine and
placebo were re-labeled injection A or B by staff who
would not enroll animals at the farm. A chute pro-
cessing order sheet was created, and a corresponding
random allocation number between 0 and 1 was
generated by an investigator not involved with
enrollment (Excel, Microsoft, Redmond, WA)... At
the ISU farm, three students, including the 1st
author allocated the animals to treatment cohorts
(Funk et al., 2009).
Explanation
For the reader to evaluate allocation concealment, it is
necessary to know who generated the allocation
sequence, who enrolled study units into the trial and
how study units were allocated to the treatment groups.
Ideally, the person(s) who generated the random alloca-
tion sequence should not be involved in the enrolment
and assignment of study units to the treatment groups,
as this could result in bias. In the human healthcare lit-
erature, the concern of not separating allocation genera-
tion from implementation is that if the person who
generated the allocation sequence is the same person
who enrols participants or assigns treatment, knowledge
of the allocation sequence could influence them when
interviewing potential trial participants (Schulz and
Grimes, 2002). In trials in livestock populations, this
bias could occur when selecting study units for partici-
pation, or could be inadvertently introduced when com-
municating with owners/managers on potential study
units for inclusion. In some instances, owners/managers
may be the person(s) enrolling study units, in which
case they should not be aware of the allocation
sequence, for the same reasons.
Item 11
Whether or not those administering the interventions,
caregivers and those assessing the outcomes were blinded
to group assignment. If performed, how the success of
blinding was evaluated. Provide justification for not using
blinding if it was not used.
Example
Two bottles, labeled ‘A’ and ‘B’, were provided to
each feedlot, so that the feedlot personnel were blind
to the status of the vaccine. One bottle held the vac-
cine… The other bottle held the placebo, which was
the same as the vaccine but without the antigen
(VanDonkersgoed et al., 2005).
Explanation
In controlled trials, blinding (synonym: masking) refers
to the process of keeping different individuals involved in
the trial unaware of the group allocation. Blinding is
associated with internal validity and can be implemented
in most RCTs, regardless of the level of intervention allo-
cation. Often, the use of blinding is reported poorly in
livestock trials; only four of 100 randomly selected live-
stock trials with health or production outcomes, and zero
of 100 randomly selected pre-harvest food-safety trials
reported blinding of the person administering the
treatment and blinding of the outcome assessor (Sargeant
et al., 2009a,b).
Trials which failed to report blinding and randomization
in a systematic review of vaccines to prevent pink-eye in
cattle were more likely to report favourable outcomes
compared with trials that did report randomization and
blinding (47% versus 20%) (Burns and O’Connor, 2008).
This is consistent with studies in the human health litera-
ture that have observed larger treatment effects in trials not
reporting the use of blinding (Schulz et al., 1995; Juni
et al., 2001; Kjaergard et al., 2001).
It is insufficient to state that ‘staff were blinded to
intervention groups’; the process of achieving blinding
should be reported. As with allocation, the method of
blinding should be described to allow the reader to assess
the validity of the blinding. The terms ‘single-, double-
and triple-blinded’ may be used to describe the blinding,
but such terms are ambiguous; a study in the human
healthcare literature illustrated that individuals may have
different interpretations of who is blinded when these
terms are used (Devereaux et al., 2001). In addition,
study subjects in animal studies cannot be blinded, unlike
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human study subjects. Therefore, it is preferable to state
which individuals were blinded. In livestock studies
involving production, health and food-safety outcomes,
we propose that authors address three potential levels of
blinding: individuals associated with assessment of the
outcome, individuals caring for the animals and data
analysts. Individuals associated with assessment of the
outcome may include owners/managers, animal caregiv-
ers, data collectors and assessors of outcomes (Devereaux
et al., 2005). The personnel who are blinded should be
explicitly described in this item and their role in the
study should be defined (e.g. veterinarians, data analysts
and personnel in laboratories performing tests).
The rationale for blinding individuals responsible for
assessing the outcome is to prevent introduction of infor-
mation bias. If the assessor is aware of the groups, they
may over- or underestimate the outcome. Even objective
outcomes such as weight gain may be biased by the lack
of blinding. For example, in a study evaluating the impact
of an intervention on the presence of Salmonella spp. on
poultry carcasses at an abattoir, laboratory staff may
re-examine plates more frequently, looking for Salmonella
spp., if they are aware that a set of plates is associated
with a particular intervention group expected to have
higher Salmonella recovery rates. The CONSORT explana-
tion and elaboration refers to this as ascertainment bias.
Further, it is also critical that anyone responsible for
animal-care decisions is unaware of the group allocation.
Knowledge of the intervention by caregivers may lead to
differential care of the groups, which may introduce per-
formance bias. For example, a challenge trial may be
designed to assess the impact of a vaccine on the presence
of clinical signs of respiratory disease after challenge. The
study protocol may include a blinded person responsible
for allocation of the intervention (described in Item 9),
an unblinded caregiver and a blinded outcome assessor.
The primary and secondary outcomes of interest may be
the presence of sneezing and coughing at a certain time
of day, and 21-day weight gain respectively. This study
protocol may not prevent the introduction of bias if the
unblinded caregiver increases observations of a particular
intervention group and administers antibiotics to animals
in the group at an earlier stage of disease. Increased
administration of antibiotics may affect the prevalence of
clinical signs and weight gain in that group, thus intro-
ducing a bias in both outcomes, although the outcome
assessor is blind to the group allocation.
It is not always possible to use blinding, for example, if
the intervention is a comparison between a surgical treat-
ment and a medical treatment. In challenge studies, it
may be difficult to maintain blinding if challenged
animals become morbid and there is a pronounced
treatment effect.
If the study cannot be blinded, authors should describe
why it was not and how the study was adapted to eliminate
selection and/or information bias. This should include the
use of at least one objectively measured outcome.
Item 12a
Statistical methods used to compare groups for all out-
come(s). Clearly state the level of statistical analysis and
methods used to account for the organizational structure,
where applicable.
Example
The experimental unit used for statistical analyses
was individual mammary quarter. Generalized linear
mixed models were used to examine risk factors for
development of a new IMI [intramammary infec-
tion]. Specialized statistical techniques were used to
account for clustering of quarters within cows and
for clustering of cows within herds [referenced in
original article]. It was assumed that the degree of
similarity between observations within a cluster was
the same for all clusters. The main predictor of
interest was treatment, and models with the follow-
ing outcomes were analyzed: new IMI caused by any
pathogen, new major IMI, new environmental IMI,
new gram-negative IMI, and new streptococcal IMI.
For each outcome, a single model that incorporated
terms for group and treatment within group was
constructed (Sanford et al., 2006).
Explanation
A complete and accurate description of statistical analyses
allows the reader to assess the validity of the statistical
methods and the likelihood that analytical bias affected
the internal validity of the study. The statistical analysis
of RCT data should follow logically from the design of
the study. Particular care is needed for analysing data
from a trial where the units of allocation and outcome
measurement are not the same. Ignoring differences
between the unit of allocation and the unit of outcome
measurement may lead to spurious results (Donner and
Klar, 2004; Campbell et al., 2007; St-Pierre, 2007). It is
critical that authors clearly describe the statistical
approach to analysis employed to account for such a
design. Several statistical methods of data analysis may be
suitable, depending on whether the outcome measure-
ment is continuous, ordinal or binary. There are many
useful publications that appropriately describe the statisti-
cal methods to use, and consultation with a statistician in
the design and analysis stage of a clinical trial is strongly
recommended (St-Pierre, 2007). Further, authors are
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encouraged to consult texts that describe how to write
about statistical methods, as the following notes do not
cover all possible contingencies (Miller, 2005).
The statistical procedure to analyse each outcome
should be explicitly described. Authors should report
underlying assumptions associated with each analysis (e.g.
normally distributed data) and, when conducted, data
transformations should be stated and justified.
The assumption of independence and identical distri-
bution is commonly violated in livestock studies when
there are multiple repeated observations per study unit
over time and/or when study units are aggregated in
groups and the outcomes of multiple groups are con-
sidered in the analysis. Therefore, independence and
identical distribution should be considered and, where
necessary, clearly described and justified. Treating each
observation as an independent event when the organiza-
tional structure of the population implies non-indepen-
dence is a serious violation of inherent assumptions of
many statistical tests and usually leads to an overly opti-
mistic P-value (the probability of observing the data or a
more extreme result when there is no treatment effect).
The statistical approach used to account for non-indepen-
dence should be clearly described. An extension of the
CONSORT statement for clustered trials has been devel-
oped and provides recommendations for reporting this
type of trial (Campbell et al., 2004b).
Authors should provide details of all descriptive and
hypothesis testing analyses that were conducted, including
the name of the test used, such as t-test, chi-square test
for proportions, Fisher’s exact test, Mann–Whitney test or
others. If the method is novel, a reference for the
approach should be provided. If logistic regression mod-
elling is used, the level of the outcome being modelled
should be described, for example, ‘we modelled the prob-
ability of being disease positive’. For all models, authors
should indicate the data form (e.g. continuous or categor-
ical) for all variables in the model. For categorical inter-
vention variables, the referent must be clearly stated, for
example, ‘the referent level of the intervention was Treat-
ment A’. Guidelines for reporting regression models are
available (Ottenbacher et al., 2004; Tetrault et al., 2008).
Item 12b
Methods for additional analyses, such as subgroup
analyses and adjusted analyses.
Example
Bacterial and clinical cures among groups were com-
pared by chi-square tests. A stratified analysis of
treatment effects was then performed to compare
these effects with those after stratification on farm
(three levels) and pretreatment bacterial isolates
(four levels). These analyses determined whether the
treatment effects were independent of farm and
primary bacterial isolate (Guterbock et al., 1993).
Explanation
In RCTs, randomization should limit the impact of con-
founding on the study outcome. Therefore, there is
generally no need to adjust for confounding. Further,
adjustment for statistically significant baseline differences
is not recommended (Oxman and Guyatt, 1992; Brookes
et al., 2001, 2004; Hernandez et al., 2006; Wang et al.,
2007). Therefore, if authors wish to explore confounding
using multivariate analysis, the rationale for assessment of
confounding should be provided. Although confounding
by important prognostic variables should be removed
through randomization of treatments, it may still be of
interest to a researcher to investigate interactions between
the treatment groups and important covariates. If the
interactions are significant, it may be necessary to con-
duct subgroup (or strata-specific) analyses. If subgroup
analyses are used, the method should be clearly described.
However, post hoc subgroup analysis is discouraged, as
these comparisons may result in spurious results by
increasing the number of comparisons evaluated, and the
sample size is generally calculated on the basis of the
full sample rather than the sample size provided by a
subgroup. Therefore, subgroup analyses generally do
not have credibility, and their findings are often not
confirmed by subsequent studies.
Subgroup analysis often employs multivariate regres-
sion models with interaction (cross-product) terms to
assess the presence of effect modification. If regression
modelling is used, the authors should describe the test
used to assess the significance of the interaction term.
Further, the outcome being modelled, the variables of
interest and covariates included in the model should be
clearly stated. For all models, authors should indicate the
data form, continuous or categorical, for all variables in
the model. For categorical variables, the referent should
be identified. Authors are encouraged to refer to guide-
lines for reporting regression models (Ottenbacher et al.,
2004; Tetrault et al., 2008). This information is necessary
to allow the reader to assess the validity of the adjusted
or subgroup analyses and the likelihood of analytical bias.
Results
Item 13a
Flow of study units through each stage for each level of
the organizational structure of the study (a diagram is
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strongly recommended). Specifically, for each group,
report the number of study units randomly assigned,
receiving intended treatment, completing the study proto-
col and analysed for the primary outcome.
Example
Of the 939 cows (3,731 mammary quarters) enrolled
in the study, 519 were assigned to group 1 (results of
bacteriologic culture of all 4 quarter milk samples col-
lected 14 days prior to the end of lactation were nega-
tive) and 420 were assigned to group 2 (results of
bacteriologic culture of 1 or more quarter milk sam-
ples collected 14 days prior to the end of lactation
were positive). However, 111 cows in group 1 were
excluded for the following reasons: abortion (n = 10),
disease (1), death (7), removal from the herd (2), …
Similarly, 93 cows in group 2 were excluded for the
following reasons: abortion (n = 3), death (4),
removal from the herd (3), 1 or more milk samples
were not collected (12), 1 or more milk samples were
lost (1), the incorrect treatment was given (1), the
nonlactating period lasted <30 days (6), …. Thus,
data from 734 cows (408 assigned to group 1 and 326
assigned to group 2) and 2,771 quarters were included
in analyses (Sanford et al., 2006).
Twenty-eight of the 30 cows with LDA were success-
fully surgically treated with omentopexy via right
flank laparotomy or 2-step laparoscopy-guided
abomasopexy and discharged from the hospital. One
cow in each surgery group died or was euthanatized
(both at day 7 after surgery) because of failure to
respond to treatment and subsequent multiorgan
failure. Necropsy revealed extensive hepatic lipidosis
in both cows, and data from both were included in
the statistical comparison (Wittek et al., 2009).
Explanation
Authors should include the organizational levels applica-
ble to their trial. Table 2 contains a list modified from
the ‘CONSORT: Explanation and Elaboration’ document
with the details required to chart the progress of owners/
managers and study units through an RCT. For example,
if the study solicited participation from randomly selected
Table 2. Information required to document the flow of participants through each stage of a randomized controlled trial
Stage No. included No. not included/excluded Rationale
Enrolment Owners/managers
evaluated for
potential enrolment
Owners/managers who did not meet
the inclusion criteria
Owners/managers who met the
inclusion criteria, but declined to be
enrolled
This information aids in determining whether
animal owner/managers were likely to be
representative of all owners/managers with
similar livestock operations; it is relevant to
assessment of external validity
Herds/sites/pens/animals
evaluated for potential
enrolment
Proportion of herds/sites/pens/
animals meeting inclusion criteria
but not enrolled (at each level of
organization)
This information aids in determining whether
the enrolled number (the sample population)
represents a large component of the
potential study population within the facility;
it is relevant to assessment of external validity
Randomization Study units randomly
assigned
May need to be described at more
than one level of organization (e.g.
animals randomly assigned to pens,
pens randomly assigned to
treatments)
Crucial for defining trial size and assessing
whether a trial has been analysed by
intention to treat
Treatment
allocation
Study units that received
treatment as allocated,
by study group
Study units that did not receive
treatment as allocated, by study
group
Important for assessment of internal validity
and interpretation of results
Follow-up Study units that completed
intervention protocol
as allocated, by study group
Study units that did not complete
intervention protocol allocated, by
study group
Important for assessment of internal validity
and interpretation of results. May also provide
information about the feasibility of the protocol
Follow-up Study units that received
the full intervention protocol
and completed follow-up as
planned, by study group
Study units that received the full
intervention protocol by study group,
but did not complete
follow-up as planned
Important for assessment of internal validity and
interpretation of results. May also provide
information about the feasibility of the
protocol
Analysis Study units included in main
analysis, by study group
Study units excluded from main
analysis, by study group
Crucial for assessing whether a trial has been
analysed by intention to treat; reasons for
excluding participants should be given
J. M. Sargeant et al. The REFLECT Statement: Elaboration
ª 2010 Blackwell Verlag GmbH • Zoonoses Public Health. 57 (2010) 105–136 123
farms identified in a county-level database, then the
number of farms that refused to participate should be
reported. For a trial conducted on a single feedlot, which
was selected by convenience, the narration/flow chart
might begin with a discussion of the feedlot pens selected
from within the feedlot to be included in the study.
Flow of study units in challenge trials of short duration
with no losses, no protocol failure and no change in organi-
zational structure to report may be reported effectively in
the text. However, for more complex trials, authors should
strongly consider including a flow chart of the trial. The
complexity of the organizational structure is important to
understand the external validity, whereas loss to follow-up
and protocol failures affect internal validity. Thus, the
reader needs this information to assess the validity of the
study. For example, loss to follow-up of barns from one
production system or site may have different implications
than exclusion of barns distributed across multiple produc-
tion companies or sites. Likewise, in livestock-production
operations, animals might be sold before outcomes are
assessed and, if the sale was associated with the outcome,
this might result in biased results. The reader may find a
chart depicting these changes easier to follow than reading
a description of events. The description of losses to follow-
up or protocol deviations should clearly identify these
features at both the level of treatment allocation and the
level of outcome measurement.
An example of loss to follow-up in a livestock study
could be a study that assessed the impact of antibiotics
on weight gain in the first 21 days post-arrival. For cattle
that die prior to the end of the study period, weight gain
cannot be assessed; therefore, these study units are lost to
follow-up. In the same study, it is possible that one or
more farms could decide to terminate their involvement
prior to the end of the trial. In this example, the number
of farms, pens and animals that were lost to follow-up
should be described. In a food-safety trial assessing the
impact of a vaccine on E. coli O157 levels in carcasses,
carcasses eliminated during processing because of con-
demnation cannot be assessed for E. coli O157 status and
are an illustration of study units lost to follow-up. Sam-
ples that are collected but subsequently lost in transit, or
have illegible labels preventing accurate identification, are
also examples of follow-up losses.
Item 13b
Describe protocol deviations from study as planned,
together with reasons.
Examples
A random binary selection process was used to
determine which pen of each pair received vaccine
product, except that in a few circumstances one pen
of a pair had already received its arrival processing
before enrollment in the study; therefore, the other
pen received the vaccine (Smith et al., 2009).
Choice of surgical technique was assigned systemati-
cally to 1 of 2 groups in alternating sequence when the
situation permitted. However, because the study was
conducted on farms, choice of technique was often
influenced by factors such as needs of the producer,
availability of laparoscopic instruments, or constraints
of the teaching environment (Roy et al., 2008).
Explanation
Any deviations from the trial protocol as defined prior to
the start of a trial should be described; if no deviations
occurred, this should also be clearly stated. Types of
deviations that should be described include unplanned
changes in the intervention(s), as well as changes to the
way in which data were collected or analysed. If a flow
diagram was used to describe participant numbers at each
stage of the trial (Item 13a), it may be possible to detail
some or all of the protocol deviations in this diagram. In
particular, if the trial is not being conducted under the
‘intention-to-treat’ principle, the flow diagram can be
used to indicate the exclusion of study units that were
not found to meet eligibility criteria (Item 16) post-ran-
domization. However, merely stating that a deviation
occurred is not enough to justify post-randomization
exclusion – details of the deviation and the reasons for
the exclusion must both be provided. The number of
study units that withdrew prior to collection of outcome
data should also be described; if outcome data are col-
lected for all enrolled study units, this should be stated.
Item 14
Dates defining the periods of recruitment and follow-up.
Example
Of 437 cows (1748 quarters) initially enrolled at dry
off between March 27, 2002, and August 1, 2002, 419
cows remained in the study, calving between May 11,
2002, and October 5, 2002 (Godden et al., 2003).
Explanation
Knowledge of the time period during which a study took
place and over what period study units were evaluated place
the study in historical context (Moher et al., 2001d). Ani-
mal studies, especially those that are conducted outdoors
under field conditions, may be influenced by seasonal and
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related weather effects. In addition, unusual weather condi-
tions, such as extremes in temperature, drought or excessive
rain or snow, may also influence the results. The length of
the study should be included, and conditions which may be
unique to one group should be noted, although a parallel
design should avoid this issue. If a study is conducted where
the control and intervention groups start and end on differ-
ent dates, then this should be noted in the report.
Item 15
Baseline demographic and clinical characteristics of each
group, explicitly providing information for each relevant
level of the organizational structure. Data should be
reported in such a way that secondary analysis, such as
risk assessment, is possible.
Example
[Table 3.]
Explanation
The aim of reporting baseline information is to summa-
rize the actual characteristics of the study population. It
is important for those reading the trials to know the
characteristics of the study units included in the trial, to
evaluate the internal and external validity of the trial
results. Providing information on whether the treatment
groups were comparable with respect to important demo-
graphic and clinical characteristics allows the reader to
assess the comparability of groups. Therefore, for each
group, report important characteristics of study units at
all relevant organizational levels. For example, baseline
demographics may include herd-level characteristics such
as farm size, stocking density and geographical location,
whereas animal-level demographic variables may include
weight, or age and sex.
Randomized controlled trials aim to compare groups
of ‘study units’ that differ only with respect to the inter-
vention (treatment). Although formal random assignment
to treatment groups should prevent selection bias, it does
not guarantee that the groups are equivalent at baseline.
However, any differences in baseline characteristics after
randomization are the result of chance rather than bias
(Altman and Dore, 1990). Conducting and reporting sig-
nificance tests of baseline differences are not warranted
(Altman and Dore, 1990; Schulz et al., 1994; Senn, 1995)
and adjustment for variables on the basis of statistically
significant differences at baseline is likely to bias the
estimated treatment effect.
Baseline information is often efficiently presented in a
table. For continuous variables, such as weight or blood
pressure, the variability of the data should be reported,
along with average values. Continuous variables can be
summarized for each group by the mean and standard
deviation. When continuous data have an asymmetrical
distribution, a preferable approach may be to quote the
median and a percentile range (e.g. the 25th and 75th
percentiles) (Altman et al., 1983). Standard errors and
confidence intervals are not appropriate for describing
variability; they are inferential rather than descriptive sta-
tistics. Variables making up a small number of ordered
categories (such as stages of disease I–IV) should not be
treated as continuous variables; instead, numbers and
proportions should be reported for each category (Altman
et al., 1983; Lang and Secic, 1997).
Item 16
Number of study units (denominator) in each group
included in each analysis and whether the analysis was by
Table 3. [Item 15 Example] Baseline characteristics of treatment cohorts in a randomized field trial comparing an autogenous vaccine to a
placebo vaccine on three university-owned beef cattle farmsa
Iowa State University
University of Wisconsin
Farm no. 1 Farm no. 2
Vaccinated
(n = 105)
Unvaccinated
(n = 109)
Vaccinated
(n = 38)
Unvaccinated
(n = 37)
Vaccinated
(n = 38)
Unvaccinated
(n = 38)
Enrollment weight (kg)
(mean ± SD)
77 (±19) 78 (±17) 110 (±18) 107.3 (±20) 80 (±14) 80 (±13)
Parity (%)
1–3 55 (52.2) 65 (59.6) 22 (57.9) 26 (70.3) 12 (31.6) 12 (31.6)
>3 50 (47.8) 44 (40.4) 16 (42.1) 11 (29.7) 26 (68.4) 26 (68.4)
Sex (%)
Heifer 49 (46.6) 53 (48.6) 19 (50) 24 (64.9) 18 (47.4) 22 (57.9)
Bull 56 (53.4) 56 (51.4) 19 (50) 13 (35.1) 20 (52.6) 16 (42.1)
aReproduced with permission (Funk et al., 2009, p. 4588).
J. M. Sargeant et al. The REFLECT Statement: Elaboration
ª 2010 Blackwell Verlag GmbH • Zoonoses Public Health. 57 (2010) 105–136 125
‘intention-to-treat’. State the results in absolute numbers
when feasible (e.g. 10/20, not 50%).
Example
The surgical procedure was successfully completed in
59 of 60 (98.3%) cows in the laparoscopy-assisted
abomasopexy group and 60 of 60 (100%) cows in the
omentopexy (control) group. In the 1 cow in which
we were not able to successfully complete the surgical
procedure, extensive adhesion of the abomasum to the
left ventral abdominal wall resulted from a perforating
ulcer, and repositioning was therefore not possible.
That cow was euthanatized and the diagnosis con-
firmed during necropsy. Thus, data for that cow were
excluded from further evaluation (Seeger et al., 2006).
The analyses were conducted on 1367 pigs born alive
that were nursing 126 sows. The standard care study
group involved 60 litters with 647 piglets born alive,
while the maximal care study group contained 66 lit-
ters with 720 piglets born alive. One maximal care
sow was removed from the analysis because she was
suspected of having clinical porcine reproductive and
respiratory syndrome virus (PRRS) because all of her
pigs were born weak and she was anorexic. Another
sow in the standard care group was removed due to
savaging. All pigs nursing these sows were removed
from the study. In addition, 107 pigs died before
reaching 16 d of age, and so could not be included
in the analysis of the 16-d BW (Dewey et al., 2008).
In order to evaluate the measure of effect, univari-
able as treated analysis (AT) and intention to treat
(IT) was used (Ellis-Iversen et al., 2008).
Explanation
The number of study units analysed in each intervention
group for each outcome is critical for understanding the
internal validity of the study. This information allows the
reader to assess loss to follow-up and protocol deviations
for all outcomes, as Item 13 addressed only the primary
outcome. Presenting the number of participants for bin-
ary outcomes is important, because the event frequency
should be taken into account when interpreting effect
measures such as the risk ratio.
Intention-to-treat analysis relates to the treatment of
study units that have completed the study; therefore, an
outcome is available. Intention-to-treat analysis means
that study units are maintained in their allocated group
regardless of any protocol deviations, and that randomi-
zation is preserved. Protocol violations commonly occur
when animal caregivers deviate from the protocol. For
example, a caregiver may decide to add an additional
antibiotic if they believe the animal is not responding to
the randomly assigned treatment. A protocol violation
may also occur if a poultry carcass is deemed eligible for
inclusion in a processing-level trial, but is sent for re-pro-
cessing and thereby not available for sampling as part of
the regular processing system.
Intention-to-treat analysis represents the combined
effect of the application of the protocol as well as the pro-
tocol itself, and may yield different results from analyses
that only include ‘per-protocol’ study units. Inclusion of
intention-to-treat and per-protocol analysis is strongly
recommended when assessing protocols that involve
changing management practices. Different outcomes from
intention-to-treat and per-protocol analysis may suggest
problems with the implementation of the management
practices rather than the actual practices. For example, in
a study on the impact of biosecurity practices on disease
rates on swine farms, some farms may not conscientiously
apply the biosecurity practices and violate the assigned
protocol. In this instance, and assuming that biosecurity
does reduce disease rates, the intention-to-treat analysis
would have a smaller treatment effect than the ‘per-proto-
col’ analysis. The difference between the two analyses
would have resulted from compliance issues rather than
biological efficacy of the biosecurity practice per se.
Understanding the nature of protocol violations may be
valuable to future research and recommendations. Inten-
tion-to-treat analysis might suggest that the proposed
protocol is not effective; however, subsequent per-proto-
col analysis may suggest that, when consistently applied,
the practices are efficacious. Such information is useful in
designing further producer programmes.
The difference between per-protocol and intention-to-
treat analysis may not be applicable when the opportunity
for protocol violation is rare, as occurs with challenge
studies of short duration which involve a onetime appli-
cation of the intervention.
Item 17
For each primary and secondary outcome, a summary of
results for each group, accounting for each relevant level
of the organizational structure and the estimated effect
size and its precision (e.g. 95% confidence interval).
Example
[Table 4.]
Explanation
For each primary and secondary outcome reported in
Item 6, a summary outcome should be reported for each
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intervention group. The rationale for providing this infor-
mation is to allow the reader to assess the clinical rele-
vance as well as the statistical significance of the
differences between the interventions groups, information
that is better conveyed by summary effect measures rather
than by the sole use of P-values. Further, as meta-analyses
and stochastic modelling are sometimes conducted several
years after primary studies are reported, it is also
advisable to provide raw summary data for all relevant
subpopulations.
For continuous outcomes, the mean and standard devi-
ation should be reported with the number in each group,
rather than reporting the mean difference. When report-
ing proportions from binary data, include the absolute
numbers as well as the percentage or proportion (10/20
combined with 50% or 0.5%).
A contrast measure (‘effect measure’) between the
groups should also be included. For binary outcomes, this
may be the rate ratio, risk ratio, odds ratio, rate differ-
ence or risk difference. For survival data, the most com-
monly used effect measure is the hazard ratio. For
continuous data, the effect measure generally is the differ-
ences in mean values among intervention groups. For
each effect measure, the 95% confidence interval should
be reported. If authors wish to include the P-value, it
should be in addition to, not a substitute for, the 95%
confidence interval. Confidence intervals convey consider-
ably more information than P-values, and are preferred
(Gardner and Altman, 1986).
It should be clear whether the effect measure was unad-
justed (i.e. a bivariable comparison between the interven-
tion groups) or whether it was adjusted for confounding
variables (not encouraged), non-independence or both.
Given the impact of the extent of the intra-cluster corre-
lation on the power of the study, the intra-cluster correla-
tion coefficient or k statistic for each outcome should
also be provided (Donner, 2000). When interaction is
present, effect measures for each level of the interacting
variable should be reported.
Results should be reported for all planned analyses,
including those that did not find a statistically significant
association between the intervention and the outcome. If
the study was conducted at multiple sites, site-specific
summary information should be provided as well as over-
all summary information. This will allow readers to assess
variation in the effect measure across sites.
It is not recommended to report the parameter esti-
mates for logistic or Poisson models, as it is unnecessary
work for the reader to convert the parameter estimate to
an effect measure. In addition, it may not be possible to
calculate the effect measure if the authors failed to specify
whether a deviation from the mean versus reference cod-
ing was used in the modelling described under Item 12.
Item 18
Address multiplicity by reporting any other analyses per-
formed, including subgroup analyses and adjusted analy-
ses, indicating those pre-specified and those exploratory.
Example
The rate of bacterial cures did not differ (P = 0.61)
between oxytocin-treated and antibiotic-treated cows
(Table 3 [in original citation]). Clinical cure rates
were nearly identical (P = 0.99) for the three
treatment groups. Treatment did not significantly
influence clinical or bacterial cure rate when the data
were stratified by herd (P = 0.27) (Table 3). When
the data were stratified by organism isolated, bacte-
rial cure rate did not differ by treatment (Table 4 [in
original citation]). Clinical cure rate did not differ
by treatment, except that treatment with either anti-
biotic improved clinical cure rate (P = 0.02) for the
category of other bacteria (Table 4) (Guterbock
et al., 1993).
Explanation
As the number of analyses using the same data
increases, so does the risk of false-positive findings
Table 4. [Item 17 example] Effect of tilmicosin (MIC) and tulathromy-
cin (DRAX) on feedlot performance of feedlot heifer calves at moder-
ate risk for bovine respiratory diseasea
Experimental group
Performance variable MIC DRAX SEM P-value
No. of pens 10 10
No. of heifers 2250 2244
Processing weight (lb) 604 603 0.90 0.70
DOF at terminal implant 137 137 0.14 0.34
Terminal implant weight (lb) 1015 1024 2.48 0.03*
DDMI at implant (lb) 18.7 19.2 0.14 0.03*
ADG at implant (lb/day) 3.02 3.09 0.02 0.03*
DMC at implant (lb/lb) 6.57 6.50 0.06 0.38
DOF at harvest 218 218 – 1.0
Final weight + (lb) 1243 1244 2.35 0.86
Final weight ) (lb) 1246 1246 2.38 0.99
Final DDMI (lb) 20.0 20.3 0.18 0.28
Final ADG + (lb/day) 2.92 2.9 0.008 0.28
Final ADG ) (lb/day) 2.87 2.87 0.009 0.99
Final DMC + (lb/lb) 6.87 6.95 0.06 0.32
Final DMC ) (lb/lb) 6.97 7.02 0.05 0.49
aReproduced with permission (VanDonkersgoed et al., 2008, p. 293)
*Statistically significant differences (P £ 0.05).
+, weight of dead animals added; ), weight of dead animals
removed; ADG, average daily gain; DDMI, daily dry matter intake;
DMC, dry matter conversion; DOF, days on feed.
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(Tukey, 1977). Examples of multiple analyses include
evaluating the intervention against multiple outcomes;
performing multiple analyses based on control of differ-
ent potential confounding variables or within levels of
an interaction variable and subgroup analysis, wherein
interventions are evaluated within a subgroup of study
units on the basis of an important characteristic (e.g.
age group). Multiple outcomes are commonly used in
published trials. An evaluation of 100 livestock health-
and-production trials and 100 pre-harvest food-safety
trials reported a mean number of outcomes per trial of
9.5 (range, 1–41) and 8.5 (range, 1–51) respectively (Sar-
geant et al., 2009a,b). In trials with large numbers of
outcomes, the risk of a type I error is substantial, and
significant associations may be over interpreted. Studies
with multiple outcomes and/or subgroup analyses also
have a high risk of a type II error, as the power of the
study is usually calculated for the primary comparison
and not for additional analyses.
As discussed, subgroup analysis may be planned and
described a priori (preferred) or may be included as a post
hoc decision on the basis of preliminary analyses. If the
latter is the case, the post hoc nature of the decision
should be clearly stated, and the results of the subgroup
analysis should be described as exploratory. Experience
from human healthcare suggests that authors should resist
the temptation to perform post hoc subgroup analyses
(Yusuf et al., 1991; Oxman and Guyatt, 1992; Assmann
et al., 2000; Brookes et al., 2004; Lagakos, 2006). Analyses
that were pre-specified in the trial protocol are much
more reliable than those suggested by the data. Authors
should already have indicated which analyses were pre-
specified in Items 2, 5, 6 and 12.
When subgroup or adjusted analyses are performed,
information should already have been provided on the
specific subgroups that were analysed and the reasons for
such analyses (see Item 12). All subgroup analyses that
were performed should be reported, regardless of the
results; bias may result from selective reporting of sub-
group analyses. Results from any formal tests of interac-
tion (Item 12b) should be provided in terms of estimated
differences in the intervention effect in each subgroup,
including a confidence interval, rather than only a
P-value. A recent study reported that 59 of 97 trials
involved subgroup analyses, but only 46% reported inter-
action tests for some or all subgroup analyses (Wang
et al., 2007). Another study, involving 63 RCTs, found
that only 11 of 39 RCTs with subgroups included tests of
interaction (Hernandez et al., 2006). Additionally, details
on analyses and justifications for analyses should be
provided whenever adjustments are made for baseline
variables. If the study included such adjustments, authors
should specify whether the adjustments and selection of
adjusted variable(s) were planned. Both unadjusted and
adjusted result should also be provided.
Item 19
All important adverse events or side effects in each inter-
vention group.
Examples
Postsurgical complications were observed in 7
(11.6%) cows of the abomasopexy group, which did
not differ significantly (P = 0.163; Fisher exact test [2-
sided]) from the number of cows with postsurgical
complications (2 [3.3%]) in the control group. Two
cows in the abomasopexy group developed moderate
localized peritonitis that was more severe than
expected after the surgical procedure. Peritonitis was
diagnosed on the basis of clinical signs (fever, tense-
ness of the abdominal wall, and moderate decrease in
general condition) and results of transabdominal
ultrasonography. Furthermore, three cows developed
cellulitis at the abomasopexy site, which was recogniz-
able as a phlegmonous swelling of the abdominal wall,
and 2 cows had a relapse of the LDA after they had
kicked the gauze bandage off. For both cows with
relapse, a second laparoscopy-assisted abomasopexy
was successfully performed. None of the cows in the
control group had relapse of the LDA, but two cows
developed a purulent infection at the omentopexy site.
All wound infections (three cows with cellulitis in the
abomasopexy group and two cows with purulent
infection in the control group) resolved after paren-
teral administration of an antimicrobial for several
days (Seeger et al., 2006).
Two hundred and sixty-six animals were allocated to
the LA 30 group, 265 animals were allocated to the
LA 20 group, and 266 animals were allocated to the
FLOR group. There were no adverse reactions in any
of the experimental groups (Schunicht et al., 2002).
Explanation
Many interventions have unintended and often undesir-
able effects in addition to intended effects. Readers need
information about the harms as well as the benefits of
interventions to make rational and balanced decisions.
The existence and nature of adverse effects can have a
major impact on whether a particular intervention will be
deemed acceptable and useful. In livestock studies,
adverse reactions would include any occurrence that may
affect animal health, appearance or performance. Further,
an adverse event may include reduced meat quality or
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safety. For example, studies of management practices dur-
ing transportation may observe negative impacts on the
carcass grade or increased condemnations, and such
adverse events should be reported.
Not all reported adverse events observed during a trial
are necessarily a consequence of the intervention; some
may be a consequence of the condition being treated.
Randomized controlled trials offer the best approach for
providing safety data as well as efficacy data, although
they cannot be relied upon to detect rare adverse effects.
At a minimum, authors should provide estimates of the
frequency of the main severe adverse events and reasons
for treatment discontinuation separately for each inter-
vention group. If animals experience an adverse event
more than once, the data presented should refer to num-
ber of affected animals; number of adverse events may
also be of interest.
Discussion
Item 20
Interpretation of the results, taking into account study
hypotheses, sources of potential bias or imprecision, and
the dangers associated with multiplicity of analyses and
outcomes. Where relevant, a discussion of herd immunity
should be included. If applicable, a discussion of the rele-
vance of the disease challenge should be included.
Example
The logistics of conducting research with privately
owned cattle meant that we often did not know
when or where pens of cattle were marketed, or we
were unable to be at the site of harvest; therefore,
pens of cattle were enrolled by convenience. We do
not believe that this practice introduced selection
bias because pens of cattle were randomly assigned
to vaccine treatment initially and because research
personnel were blind to laboratory results when
enrolling pens for the current study. We found no
evidence of selection bias based on comparing the
number of cattle per pen and the number of days
elapsing between arrival processing and reprocessing
in this study and the larger longitudinal study from
which these pens were enrolled (Smith et al., 2009).
Explanation
To encourage consistent format with the CONSORT
statement, the authors of the REFLECT statement agree
with the recommendation of the CONSORT Explanation
and Elaboration document, which proposes that authors
follow the five recommendations presented in the Annals
of Internal Medicine (Moher et al., 2001d): (1) brief syn-
opsis of the key findings; (2) consideration of possible
mechanisms and explanations; (3) comparison with rele-
vant findings from other published studies (whenever
possible including a systematic review combining the
results of the current study with the results of all previous
relevant studies); (4) limitations of this study (and meth-
ods used to minimize and compensate for those limita-
tions) and (5) a brief section that summarizes the clinical
and research implications of the work, as appropriate.
Most, if not all, trials will have some limitations.
Therefore, the discussion section should include a discus-
sion of these limitations and the possible implications
they might have on the conclusions from the trial. The
discussion of study limitations should include any
potential biases, including the presence of uncontrolled
confounding factors or differences among intervention
groups (Campbell et al., 2004b), or the potential for
selection bias. If possible, the impact of these potential
biases should be quantified. Sensitivity analyses that illus-
trate the magnitude of confounding, misclassification or
selection, which would be required to change the infer-
ence of the study, are preferable to statements such as
‘results should be interpreted with caution because of the
potential for confounding/misinformation/selection bias’.
If employed, these sensitivity analyses should be described
in the methods and materials, and the results sections.
If blinding or formal randomization to treatment
group was not used, a discussion of the implications and
objectivity of the outcome (for non-blinded studies)
should be included. Authors should also discuss the num-
ber of subjects per intervention group that did not com-
plete the study and how this may have affected the results
and conclusions.
A consideration of potential imprecision in the out-
come measure also may be appropriate. Imprecision may
be introduced into a study at a number of points, such as
when the primary outcome is measured (Item 6) or dur-
ing the determination of whether a study unit meets the
eligibility criteria (Item 3a). For instance, a blood test
may have been validated in adult cows, but not in calves,
or a laboratory technician may not be familiar with how
to interpret a blood smear from a particular species. As
this kind of issue has the potential to increase impreci-
sion, such issues should be mentioned in the discussion.
Authors should address the biological and practical
importance of the work carried out, while not extrapolat-
ing the results of their studies beyond the limits of their
data. If the trial included the evaluation of multiple
outcomes, the potential for type I errors should be
discussed. Conversely, if no significant associations with
the intervention were observed, authors should not inter-
pret this as evidence of the truth of the null hypothesis.
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In particular, failure to reject the null hypothesis in a
superiority study should not be interpreted as evidence of
equivalence (see Item 6) (Jones et al., 1996). The statisti-
cal power of the trial should already be clear from the
methods and materials.
When appropriate, authors should also discuss the
potential effects of herd immunity, given the study design
chosen, i.e. individual or clustered allocation. An example
of the possible effects of herd immunity would be the
evaluation of vaccine efficacy. If a vaccine is efficacious,
then one would expect the control (non-vaccinated)
group also to receive some benefit because of interruption
of disease transmission, if they are in contact with the
vaccinates. Therefore, when animals within groups are
allocated to vaccine, or when groups within a common
housing area are allocated to vaccine, vaccine efficacy the-
oretically measures only the direct benefits of vaccination
and is probably an underestimate of true vaccine efficacy.
Thus, the choice of control group and the implications of
that choice in terms of possible herd immunity should be
discussed when applicable.
When challenge models are used, the discussion should
include a consideration of the degree, to which the
pathogen represents wild-type pathogens, and the dose
and route of administration used in the study should be
compared with the dose and route of infection occurring
in a natural disease challenge.
Item 21
Generalizability (external validity) of the trial findings.
Example
Although extrapolation of results obtained in
experimentally infected pigs to the field situation
should be done with caution, the infection model
used allows studying the effects of infections with
Mycoplasma hyopneumoniae of different virulence in
a standardized and reproducible way (Villarreal et al.,
2009).
The external validity of the study may have been com-
promised to some extent because of the close proxim-
ity of the experimental population to the regional
agricultural college (Taveros and More, 2001).
Explanation
The external validity of a study refers to the degree to which
the study results can be generalized beyond the study
population (Rothwell, 2005). External validity may vary,
depending on the application for which the reader of the
trial is considering using the intervention. Factors involved
in determining external validity include the characteristics
of the study units and study population, the trial setting
and the interventions and the outcomes measured (Roth-
well, 2005). For instance, there are often differences in the
housing and management of young stock, compared with
those of mature animals or animals in the finishing produc-
tion stages. In ruminant animals, trials conducted in
pre-weaned animals may not be relevant to post-weaned
animals because of differences in nutritional physiology.
Therefore, when relevant, possible limitations with extend-
ing the results of a trial to animals in different production
stages should be discussed. To allow the reader to assess
external validity, trial reports should include sufficient
information on (1) eligibility criteria (Item 3), (2) trial set-
ting and location (Item 3), (3) interventions and adminis-
tration methods (Item 4), (4) outcome definitions (Item 6)
and (5) the recruitment and follow-up periods (Item 14).
However, the authors should also provide their own inter-
pretation of the external validity of the results.
Of particular relevance to livestock production is the
applicability of challenge trials. There may be substantive
differences between natural and artificial disease chal-
lenges, including potential differences in the exposure
dose, the strain(s) used and the route of administration.
Challenge studies may also use design features such as
restriction of the population and the study setting to
reduce the potential for confounding to bias the outcome.
However, when challenge trials are conducted in narrowly
selected populations of animals, the study population
may not represent the target population (e.g. on the basis
of age or weight, or whether they are free of other impor-
tant pathogens that might be encountered under com-
mercial conditions). Challenge trials are often conducted
in animals housed individually or in small groups in lab-
oratory settings, which may not be representative of the
environment that the target population experiences. Thus,
although challenge trials may provide strong preliminary
evidence of treatment efficacy, their external validity will
be not as strong as that of an RCT conducted under
commercial conditions.
Trials conducted in research herds also may use differ-
ent pen sizes or animal densities, compared with com-
mercial settings, and this will impact external validity.
Similarly, RCTs conducted at a single commercial site
may not be representative of the variety of settings possi-
ble, and the authors should acknowledge this.
In addition, information on product safety, product
quality and welfare of study subjects may be useful to
readers to decide on the applicability of the results.
Item 22
General interpretation of the results in the context of
current evidence.
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Example
In the present study, we evaluated the possible effi-
cacy of single cow calving pens for preventing neo-
natal calf diseases. Utilizing single cow calving pens
that are cleaned between uses did not provide added
protection to calves against calf diseases. Husbandry
practices other than maternity pen management
could have been relatively more important determi-
nants of preweaning health than use of single cow
calving pens. While it might be true that there really
is little to no added protection provided by single
cow calving pens against neonatal calf diseases, cau-
tious interpretation of the current results is in order
due to lack of corroborative data since no studies
had previously attempted to address similar ques-
tions using the study design employed in the present
study. These findings are inconclusive (Pithua et al.,
2009).
Explanation
When discussing the results of the study, the researcher
should consider and include the broader impacts of the
results relative to issues including, but not limited to, pol-
icy, societal welfare and concern, and industry and stake-
holder concern. At a minimum, authors should discuss
results of the study in the context of all previous work,
regardless of whether the results are supportive or not. If
authors used a Bayesian analysis, it is recommended that
the description include estimates in terms of the results
from previous studies. If similar studies do not exist or
are not available for review, the authors should indicate
this as a limitation to their results. By placing the results
in the context of prior research, authors allow readers to
interpret the results of available studies relative to chro-
nological changes in animal populations (e.g. herd sizes
and management practices), disease processes and inter-
ventions. Authors should avoid including post hoc state-
ments about the cost benefit or cost effectiveness of the
intervention unless that was a stated purpose of the man-
uscript, and the methods for such analyses were described
in Items 6 and 12.
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